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Abstract 
The Candida genus consists of approximately 200 species of fungi and collectively 
represents a highly heterogenic group. Clinically, the most important specie is Candida 
albicans, an opportunistic fungal pathogen of humans that frequently causes superficial 
infections of oral and vaginal mucosal surfaces of debilitated individuals. This 
microorganism is, however, also commonly encountered as a commensal in healthy 
individuals where it is a component of the normal microflora. Nowadays, non-Candida 
albicans Candida (NCAC) species such as Candida glabrata, Candida parapsilosis and 
Candida tropicalis are also becoming frequently identified as potential human pathogens. 
Thus, the principal aim of this thesis was to obtain significant insight into the virulence 
mechanisms of Candida species, with special relevance to those colonising the vaginal 
tissue, as well as to evaluate their resistance to new antifungal agents. 
The treatment of human infections caused by Candida (candidosis) is difficult, 
especially due to the eukaryotic nature of fungal cells. Furthermore, several Candida 
species exhibit both intrinsic and acquired resistance to common antifungal agents and 
biofilms produced by Candida are also less susceptible. Thus, the first goal of this thesis 
was to perform a screening of the antifungal potential of natural plant extracts (Castanea 
sativa, Filipendula ulmaria, Rosa micrantha and Cistus ladanifer) and four phenolic 
compounds (gallic acid, catechin, luteolin and quercetin), identified from these plants, 
against C. albicans, C. glabrata, C. parapsilosis and C. tropicalis.  The minimum inhibitory 
concentration (MIC) of plant extracts and phenolic compounds was determined according 
to standard methods. The antifungal potential of the phenolic compounds was also tested 
against Candida biofilms, and was assessed by quantification of colony forming units 
(CFUs). Overall, all plant extracts, as well as the phenolic compounds, especially gallic 
acid, revealed promising antifungal activity against Candida species. However, only gallic 
acid and quercetin demonstrated a slight effect against Candida species biofilms.  
Although the majority of the studies regarding Candida infection of human 
mucosal surfaces often include only single species, often candidosis is associated with 
mixed colonisation. The second aim of this research was to examine the interactions and 
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expression of virulence factors by C. albicans and C. glabrata using a reconstituted human 
vaginal epithelium (RHVE). The pathogenesis of C. albicans and C. glabrata single and co-
infections were investigated using peptide nucleic probe fluorescent in situ hybridization 
(PNA FISH), confocal laser scanning microscopy (CLSM) and a novel qRT-PCR protocol for 
Candida quantification in the tissues. RHVE damage was evaluated by measuring lactate 
dehydrogenase activity. Candida virulence gene (HWP1, ALS, EPA, PLB, PLD and SAP) 
expression was evaluated by qRT-PCR. It was shown that although C. albicans was a 
higher coloniser and invader of vaginal tissue, than C. glabrata, the invasiveness of C. 
glabrata strains was enhanced in the presence of C. albicans. Additionally, the results 
suggest an important role of HWP1, PLD1 and ALS3 virulence factors in C. albicans and C. 
glabrata pathogenicity. 
It is known that several environmental factors may be altered in vivo, to facilitate 
the conversion of Candida from a harmless commensal to a pathogenic organism. In the 
vaginal environment, hormonal changes are amongst such influencing factors. Therefore, 
the effect of progesterone (hormone) in C. albicans biofilm formation and RHVE 
colonisation and invasion was examined, using the same techniques described above. It 
was found that progesterone decreased the capacity of C. albicans to form biofilms and it 
was shown that C. albicans was a higher RHVE coloniser in the absence of progesterone. 
Gene expression by C. albicans infecting the vaginal epithelium suggests an important role 
of BCR1 and HWP1 virulence factor in C. albicans pathogenicity. 
In summary, this work emphasised the importance of studying new natural products as 
potential antifungal agents and also provided more insight into the mechanisms of vaginal 
infections caused by Candida species, in mono and mixed cultures, as well as in the 
presence of progesterone.  
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Sumário 
O género Candida consiste em aproximadamente 200 espécies de fungos que em 
conjunto representam um grupo heterogéneo. A espécie clínica mais importante é 
Candida albicans, um oportunista patogénico para os humanos, que causa 
frequentemente infeções superficiais da mucosa oral e/ou vaginal em indivíduos débeis. 
Este microrganismo é, contudo, também comummente encontrado como comensal em 
indivíduos saudáveis onde é um componente da sua microflora. Contudo, hoje em dia 
espécies de Candida não Candida albicans (NCAC), como a Candida glabrata, a Candida 
parapsilosis e a Candida tropicalis começam a ser identificadas como patogénicas. Assim, 
o principal objetivo desta tese foi obter novos conhecimentos sobre o mecanismo de 
virulência das espécies de Candida, com especial relevo para a sua colonização do trato 
vaginal, assim como determinar a resistência a novos agentes antifúngicos.  
O tratamento de infeções humanas causadas por espécies de Candida 
(candidíases) é difícil, especialmente devido à natureza eucariota das células fúngicas. 
Para além disso, muitas espécies de Candida exibem resistência intrínseca e/ou adquirida 
aos antifúngicos comuns e os seus biofilmes são também menos suscetíveis. Assim, o 
primeiro objetivo desta tese foi realizar uma avaliação do potencial antifúngico de extratos 
naturais de plantas (Castanea sativa, Filipendula ulmaria, Rosa micrantha e Cistus 
ladanifer) e de 4 compostos fenólicos (ácido gálico, catequina, luteolina e quercetina) 
identificados nessas plantas contra C. albicans, C. glabrata, C. parapsilosis e C. tropicalis. 
A concentração mínima inibitória (MIC) dos extratos das plantas e dos compostos 
fenólicos foi determinada seguindo as normas. Para além disso, o potencial antifúngico 
dos compostos fenólicos foi avaliado em biofilmes de Candida, pela quantificação do 
número de unidades formadoras de colónias. Globalmente, todos os extratos de plantas e 
os compostos fenólicos, especialmente o ácido gálico, revelaram potencial antifúngico 
contra as espécies de Candida. Contudo, só o ácido gálico e a quercetina demonstraram 
um pequeno efeito contra os biofilmes de Candida. 
Embora as infeções da superfície das mucosas sejam normalmente estudadas 
com apenas um microrganismo, sabe-se que em muitas situações as candidíases 
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ocorrem devido a uma infeção mista de Candida. Assim, o segundo objetivo foi examinar 
as interações e a expressão de fatores de virulência de C. albicans e C. glabrata em 
infeções simples e mistas, utilizando um epitélio vaginal humano reconstituído (RHVE). 
Para tal, usaram-se sondas de ácidos nucleicos de hibridação in situ, microscopia de 
confocal laser e a técnica de PCR em tempo real para a quantificação do número de 
células de Candida presentes no tecido. O dano do RHVE foi avaliado pela atividade da 
enzima lactato desidrogenase. A expressão genética (HWP1, ALS, EPA, PLB, PLD e SAP) 
da virulência da Candida foi avaliada por PCR quantitativo. Então, foi possível verificar que 
apesar de C. albicans ser muito mais colonizadora e invasora do tecido vaginal, do que a 
C. glabrata, a invasão das estirpes de C. glabrata aumentou na presença da C. albicans. 
Para além disso, os resultados obtidos sugerem um importante papel dos genes HWP1, 
PLD1 e ALS3 na patogenicidade da C. albicans e da C. glabrata. 
Sabe-se que muitos fatores ambientais podem alterar a facilidade de conversão da 
Candida de comensal para patogénica. No ambiente vaginal, as hormonas são conhecidas 
por serem um desses fatores. Por isso, foi avaliado o efeito da progesterona na formação 
de biofilmes e colonização do RHVE por C. albicans, utilizando as técnicas descritas 
anteriormente. Assim, mostrou-se que a presença de progesterona diminui a capacidade 
da C. albicans formar biofilme e colonizar o RHVE. Os resultados da expressão genética 
sugerem um importante papel dos genes BCR1 e do HWP1 na patogenicidade da C. 
albicans. 
Em suma, este trabalho realçou a importância do estudo de novos produtos 
naturais como potenciais agentes antifúngicos e permitiu ainda alcançar novos 
conhecimentos no mecanismo das infeções vaginais causadas por Candida, em culturas 
simples e mistas, bem como na presença de uma hormona. 
 
 
 
Publications within the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications within the thesis
 
 
xvi  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications within the thesis
 
 
xvii  
Publications within the thesis  
Papers in peer reviewed journals: 
Published: 
Carlos Tiago Alves, Isabel C.F.R. Ferreira, Lillian Barros, Sónia Silva, Joana Azeredo, 
Mariana Henriques. 2014. Antifungal activity of phenolic compounds identified in flowers 
from the North Eastern Portugal against Candida species. Future Microbiology 9(2), 139-
146. 
Lillian Barros, Carlos Tiago Alves, Montserrat Dueйas, Sónia Silva, Rosário Olieveira, Ana 
Maria Carvalho, Mariana Henriques, Celestino Santos.Buelga, Isabel C.F.R. Ferreira. 
2013. Characterization of phenolic compounds in wild medicinal flowers from Portugal by 
HPLC-DAD-ESI/MS and evaluation of antifungal properties. Industrial Crops and Products 
44, 104-110. 
Lillian Barros, Montserrat Dueйas, Carlos Tiago Alves, Sónia Silva, Mariana Henriques, 
Celestino Santos.Buelga, Isabel C.F.R. Ferreira. 2013. Antifungal activity and detailed 
chemical characterization of Cistus ladanifer phenolic extracts. Industrial Crops and 
Products 41, 41– 45. 
Submitted: 
Carlos Tiago Alves, Sónia Silva, Leonel Pereira, Joana Azeredo, David W. Williams, Mariana 
Henriques. 2014. Effect of progesterone on Candida albicans vaginal pathogenicity. 
Carlos Tiago Alves, Xiao-Qing Wei,  Sónia Silva, Joana Azeredo, Mariana Henriques, David 
W. Williams. 2014. Candida albicans promotes invasion and colonisation of Candida 
glabrata in a reconstituted human vaginal epithelium. 
 
 
Publications within the thesis
 
 
xviii  
Other scientific output 
Posters in conferences: 
Carlos Tiago Alves, Isabel C.F.R. Ferreira, Lillian Barros, Sónia Silva, Rosário Oliveira, 
Mariana Henriques. 2012. Antifungal activity of natural extracts from North Eastern 
Portuguese flowers against Candida biofilms. Biofilms 5 - International Conference, Paris, 
France, 10th-12th December, (228), 157-158. 
Carlos Tiago Alves, Isabel C.F.R. Ferreira, Lillian Barros, Sónia Silva, Rosário Oliveira, 
Mariana Henriques. 2012. Natural extracts from wild flowers used in Portuguese folk 
medicine like a new antifungal agents against Candida species. 11th ASM Conference on 
Candida and Candidiasis, San Francisco, USA, 29th March - 2nd April, (7A), 75-76. 
 
 
  
 
 
Contents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents
 
 xx 
 
 
 
 
 
Contents
 
 
xxi 
 
Table of contents 
Agradecimentos / Acknowledgments ............................................................................................ v 
Abstract / Sumário .......................................................................................................................ix 
Publications within the thesis ....................................................................................................... xv 
List of figures and tables............................................................................................................ xxv 
Nomenclature ......................................................................................................................... xxxiii 
Aim and Outline of the thesis ................................................................................................... xxxix 
Chapter I- General Introduction ..................................................................................................... 1 
1.1. Candida species ........................................................................................................... 3 
1.1.1. Candida albicans and non-Candida albicans Candida species ............................. 3 
1.1.2. Health Associated Infection and Co-Infections ..................................................... 6 
1.1.3. Virulence Factors ............................................................................................... 8 
I- Polymorphism ...................................................................................................... 8 
II- Adherence to biotic or abiotic surfaces ................................................................ 9 
III- Secretion of hydrolytic enzymes ........................................................................ 11 
IV- Candida Biofilms .............................................................................................. 13 
1.1.4. Antifungal Resistance ....................................................................................... 15 
1.2. Environmental factors ................................................................................................. 17 
1.3. Reconstituted human epithelium ................................................................................. 18 
1.4. References .................................................................................................................. 20 
Chapter II- Anti-candidal activity of Natural extracts/compounds from wild flowers used in 
Portuguese folk medicine ...................................................................................................... 29 
Abstract ................................................................................................................................ 31 
2.1. Introduction ................................................................................................................ 32 
2.2. Material and methods ................................................................................................. 34 
2.2.1. Preparation of plant extracts ............................................................................. 34 
2.2.2. Preparation of phenolic compounds ................................................................. 34 
Contents
 
 xxii 
2.2.3. Candida strains................................................................................................ 35 
2.2.4. Minimal inhibitory concentration determination ................................................. 35 
2.2.5. Antibiofilm activity of phenolic compounds on Candida biofilms ........................ 36 
2.3. Results and Discussion ............................................................................................... 37 
2.3.1. Antifungal activity of the plant extracts .............................................................. 37 
2.3.2. Antifungal activity of the phenolic compounds ................................................... 40 
2.3.3. Antifungal activity against biofilms of the phenolic compounds .......................... 45 
2.4. Acknowledgments ....................................................................................................... 47 
2.5. References ................................................................................................................. 48 
Chapter III- Candida albicans promotes invasion and colonisation of Candida glabrata in a 
reconstituted human vaginal epithelium .................................................................................. 53 
Abstract ................................................................................................................................ 55 
3.1. Introduction ................................................................................................................ 56 
3.2. Material and methods ................................................................................................. 58 
3.2.1. Microorganisms ............................................................................................... 58 
3.2.2. Culture of Candida ........................................................................................... 58 
3.2.3. Infection of a reconstituted human vaginal epithelium ....................................... 59 
3.2.4. Histological techniques .................................................................................... 59 
3.2.5. Peptide nucleic acid fluorescent in situ hybridization ......................................... 60 
3.2.6. Confocal laser scanning microscopy (CLSM) .................................................... 60 
3.2.7. Lactase dehydrogenase (LDH) activity .............................................................. 61 
3.2.8. Quantification of Candida species in RHVE tissue sections ................................ 62 
I- DNA extraction ................................................................................................... 62 
II- Quantification of DNA by Real-time PCR ............................................................. 62 
3.2.9. Analysis of candidal virulence gene expression ................................................. 63 
I- RNA extraction ................................................................................................... 63 
II- Synthesis of cDNA ............................................................................................ 64 
III- Primer design .................................................................................................. 64 
IV- Quantitative Real-time PCR ............................................................................... 66 
3.2.10. Statistical analysis ......................................................................................... 66 
3.3. Results ....................................................................................................................... 67 
Contents
 
 
xxiii 
 
3.3.1. In vitro single and co-infection of RHVE ............................................................. 67 
3.3.2. LDH activity as an indicator of tissue damage ................................................... 71 
3.3.3. Gene expression .............................................................................................. 72 
3.4. Discussion .................................................................................................................. 76 
3.5. Acknowledgments ....................................................................................................... 79 
3.6. References .................................................................................................................. 80 
Chapter IV- Effect of progesterone on Candida albicans vaginal pathogenicity ............................ 83 
Abstract ................................................................................................................................ 85 
4.1. Introduction ................................................................................................................ 86 
4.2. Material and methods ................................................................................................. 88 
4.2.1. Organisms and growth conditions ..................................................................... 88 
4.2.2. Effect of Progesterone on Candida albicans biofilm formation ........................... 88 
I- Quantification of cultivable cells from biofilms ..................................................... 89 
II- Quantification of biofilm biomass ....................................................................... 89 
III- Characterisation of biofilm structure ................................................................. 89 
4.2.3. Effect of progesterone on Candida albicans colonisation of RHVE ...................... 90 
I- Microscopic observation ..................................................................................... 90 
II- Quantification of Candida cells in RHVE tissue sections ...................................... 91 
II.1- DNA extraction ............................................................................................ 91 
II.2- Quantification of Candida by Real-time PCR ................................................. 92 
4.2.4. Analysis of HWP1 and BCR1 gene expression in C. albicans biofilms ................ 92 
I- Candida RNA extraction ..................................................................................... 92 
II- Synthesis of cDNA ............................................................................................. 93 
III- Gene selection and primer design for quantitative Real-time PCR ...................... 93 
        IV- Quantitative Real-time PCR (qRT-PCR) .............................................................. 94 
4.2.5. Statistical analysis ............................................................................................ 95 
4.3. Results ....................................................................................................................... 96 
4.3.1. Influence of progesterone on biofilm formation by Candida albicans .................. 96 
4.3.2. Influence of progesterone in RHVE colonisation and invasion by Candida   
albicans ..................................................................................................................... 98 
4.4. Discussion ................................................................................................................ 102 
4.5. Acknowledgments ..................................................................................................... 104 
Contents
 
 xxiv 
4.6. References ............................................................................................................... 105 
Chapter V- General conclusions and future work .................................................................... 107 
5.1. General conclusions and future work  ........................................................................ 109 
 
 
 
List of figures and tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of figures and tables 
 
xxvi  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of figures and tables 
xxvii  
List of figures 
Figure 1.1 - The growth forms of Candida species: growth as yeasts (a), production of true 
hyphae (b) and pseudohyphae (c). Adapted from [11] ...................................................... 4 
Figure 1.2 - Colonies of Candida species grown for 48 h on CHROMagar®Candida at 
37°C. Adapted from [16] ................................................................................................. 5 
Figure 1.3 - Section of the C. albicans cell wall imaged by transmission electron 
microscopy and a schematic depiction of the arrangement of the major components of cell 
wall [21] .......................................................................................................................... 6 
Figure 1.4 - Schematic of biofilm formation on a polyvinylchloride catheter surface. (a) 
Catheter surface with an adsorbed conditioning film of host proteins (black dots). (b) Initial 
yeast cell (red) adhesion to surface. (c) formation of basal microcolony layers of 
microorganisms. These anchor each microcolony to the surface. (d) completion of 
microcolony formation by addition of the upper, mainly hyphal layer and matrix material 
(yellow) that surrounds both yeasts (red) and hyphae (green). Mature biofilms contain 
numerous microcolonies with interspersed water channels to allow circulation of nutrients. 
(e) Cells released or detached from the biofilm spread into the environment, dispersing 
infections and forming new biofilms. Adapted from [98].................................................. 13 
Figure 1.5 - SkinEthic Human Epithelium (RHE). (a) oral mucosa epithelium in vivo, (b) 
reconstituted human oral epithelium in vitro, (c) vaginal mucosa epithelium in vivo and (d) 
reconstituted human vaginal epithelium in vitro. Adapted from [144-145] ....................... 19 
Figure 2.1 - Logarithm of number cells of C C. albicans ATCC 90028 (a), C. glabrata ATCC 
2001 (b), C. parapsilosis ATCC 22019 (c) and C. tropicalis ATCC 750 (d) cultured in 
different concentrations of four plant extracts, formed in SDB after 48 h. Error bars 
represent standard deviation. ......................................................................................... 39 
Figure 2.2 - Logarithm of number cells of C. albicans ATCC 90028 (a), C. glabrata ATCC 
2001 (b), C. parapsilosis ATCC 22019 (c) and C. tropicalis ATCC 750 (d) grown in 
List of figures and tables 
 
xxviii  
presence of increased concentrations of gallic acid, catechin, luteolin and quercetin, after 
48 h. Error bars represent standard deviation. Concentrations that are significantly 
different (*P<0.05, **P<0.01, *** P<0.001) of each compound control .......................... 44 
Figure 2.3 - Logarithm of number of C. albicans ATCC 90028 (a), C. glabrata ATCC 2001 
(b), C. parapsilosis ATCC 22019 (c) and C. tropicalis ATCC 750 (d) cells in the biofilm 
treated with increased concentrations of gallic acid, catechin, luteolin and quercetin, after 
24 h formed in RPMI 1640. Error bars represent standard deviation. Concentrations that 
are significantly different (*P<0.05) of each compound control ....................................... 46 
Figure 3.1 - C. albicans and C. glabrata single infection of RHVE after 24 h, assessed by 
CLSM and YTL PNA FISHTM. (A) C. albicans ATCC 90028, (B) C. albicans 324LA/94 (C) C. 
glabrata ATCC 2001, (D) C. glabrata D1 and (E) C. glabrata 585626 ............................. 67 
Figure 3.2 - C. albicans and C. glabrata strains co-infection of RHVE after 24 h, assessed 
by CLSM and YTL PNA FISHTM. (A) C. albicans ATCC 90028 and C. glabrata ATCC 2001, 
(B) C. albicans ATCC 90028 and C. glabrata D1, (C)  C. albicans ATCC 90028 and C. 
glabrata 585626, (D) C. albicans 324LA/94 and C. glabrata ATCC 2001, (E) C. albicans 
324LA/94 and C. glabrata D1 and (F) C. albicans 324LA/94 and C. glabrata 585626 ... 68 
Figure 3.3 - Relative lactate dehydrogenase (LDH) activity measured in the human vaginal 
epithelium tissue culture supernatant after 24 h incubation with different C. albicans and 
C. glabrata strains in single infection and co-infection (A- C. albicans ATCC 90028; B- C. 
albicans 324LA/94; C- C. glabrata ATCC 2001;  D- C. glabrata D1;  E- C. glabrata 
585626) ........................................................................................................................ 71 
Figure 4.1 - Cell viability [Log (CFU/cm2)] (A) and absorbance values of (B) crystal violet 
solutions (Abs CV/cm2) obtained from 24 h biofilm of C. albicans strains formed in RPMI 
buffered to pH 4 in absence or presence of 2 µM of progesterone. Error bars represent 
standard deviation. *** Statistical difference obtained when compared with absence of 2 
µM of progesterone (control) (p<0.001). ........................................................................ 96 
List of figures and tables 
xxix  
Figure 4.2 - Scanning electron microscopy of C. albicans 24 h biofilms formed in RPMI in 
the absence or presence of 2 µM of progesterone. Original magnification was ×1000 ..... 97 
Figure 4.3 - Relative BCR1 (A) and HWP1 (B) expression obtained from 24 h biofilms of C. 
albicans formed in RPMI (pH 4), in the presence and absence of 2 µM of progesterone. 
Error bars represent standard deviation. *** Statistical difference obtained when compared 
with absence of progesterone (p<0.001). ....................................................................... 98 
Figure 4.4 - Candida albicans RHVE infection after 24 h, assessed by fluorescence 
microscopy and YTL PNA FISHTM. (A) C. albicans ATCC 90028 and (D) C. albicans 558234 
adhered without progesterone, (B) C. albicans ATCC 90028 and (E) C. albicans 558234 
adhered for 24 h in the presence of 2 µM of progesterone and (C) C. albicans ATCC 
90028 and (F) C. albicans 558234 with addition of progesterone after 12 h of infection.99 
Figure 4.5 - Relative expression of the Hyphal Wall Protein 1 (HWP1) gene in the absence 
or presence (added at 0 h, or after 12h) of progesterone during C. albicans colonisation of 
reconstituted human vaginal epithelium. Error bars represent standard deviation. *** 
Statistical difference obtained compared to the absence of progesterone (p<0.001) ......101 
 
 
 
 
 
 
 
List of figures and tables 
 
xxx  
List of tables 
Table 1.1 - Examples of Candida albicans adhesins and associated host cell ligands [58]10 
Table 2.1 - Minimum inhibitory concentrations (MIC; mg/ml) of wild plant extracts against 
Candida species ............................................................................................................ 37 
Table 2.2 - Presence or absence of each phenolic compound in the studied F. ulmaria, C. 
sativa, R. micrantha, C. multiflorus and C. ladanifer extracts ........................................... 41 
Table 2.3 - Efficacy of phenolic compounds (1 mg/ml) identified in wild plants from North 
Eastern Portugal Candida species .................................................................................. 42 
Table 2.4 - Minimum inhibitory concentrations (MIC; mg/ml) values obtained with gallic 
acid, catechin, luteolin and quercetin against Candida species ....................................... 43 
Table 3.1 - Primers used for Real time-PCR screening for C. albicans and C. glabrata ..... 63 
Table 3.2- Forward (FW) and reverse (RV) housekeeping primers used for Real-time PCR 64 
Table 3.3 – Forward (FW) and reverse (RV) primers used for Real-time PCR ................... 65 
Table 3.4 - Summary findings of C. glabrata and C. albicans single and co-infection of 
reconstituted human vaginal epithelium at 24 h ............................................................. 70 
Table 3.5 - Relative expression of Hyphal Wall Protein 1 (HWP1), Agglutinin-like Sequence 
(ALS), Phospholipase (B and D) and Secreted Aspartyl Protease (SAP) gene families after 
24 h of reconstituted human vaginal epithelium single and co-infection by different 
Candida albicans and Candida glabrata strains using quantitative RT-PCR ...................... 74 
Table 3.6 - Relative expression of Epithelial Adhesin (EPA) gene family after 24 h of 
reconstituted human vaginal epithelium single and co-infection by Candida albicans and 
Candida glabrata using quantitative RT-PCR ................................................................... 75 
Table 4.1 - Forward (FW) and reverse (RV) primers used for Real-time PCR ..................... 94 
List of figures and tables 
xxxi  
Table 4.2 - qRT-PCR quantification of C. albicans infecting the reconstituted human vaginal 
epithelium for 24 h in the presence or absence of 2 µM of progesterone ......................100 
List of figures and tables 
 
xxxii  
 
 
 
 
 
Nomenclature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nomenclature 
 
 
xxxiv  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nomenclature 
 
xxxv  
Symbols 
ºC- Degrees 
g- Gravity 
%- Percent 
P- Significance value 
Ct- Threshold cycle 
$- United State of America Dollar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nomenclature 
 
 
xxxvi  
Abbreviations 
Abs- Absorbance 
ACT1_alb- Actin Candida albicans 
ACT1_gla- Actin Candida glabrata 
AIDS- Acquire Immune Deficiency Syndrome 
ALS- Agglutinin like sequence gene 
ANOVA- Analysis of variance 
AP- Alternative pathway 
ATCC- American Type Culture Collection 
BCR- Biofilm and Cell Wall Regulator  
cDNA- complementary Deoxyribonucleic Acid 
CFU- Colony Forming Units 
CHROMagar- Chromogenic Media agar 
CLSM- Confocal Laser Scanning Microscopy 
CV- Crystal Violet 
DAPI- 4',6-diamidino-2-phenylindole 
DNA- Deoxyribonucleic Acid 
dNTP- deoxynucleoside triphosphate 
ECM- Extracellular matrix 
EPA- Epithelial adhesin gene 
Epa- Epithelial adhesin gene protein 
EPS- Extracellular polymeric substances 
FCT- Fundação para a Ciência e Tecnologia 
FFPE- Formalin-Fixed Paraffin-Embedded 
FH- Factor H 
FISH– Fluorescent in situ Hybridization 
GPI- Glycophosphatidylinositol anchor protein 
h- hour 
HIV- Human Immunodeficiency Virus 
Nomenclature 
 
xxxvii  
HLP- (Haemolysin Like Protein) 
HPLC- High Performance Liquid Chromatography 
HWP- Hyphal Wall Protein 
kDa- Dalton 
LDH- Lactate Dehydrogenase 
LIP- Lipases 
Log- Logarithm to base 10 
MIC- Minimal Inhibitory Concentrations 
min- minute 
mRNA- messenger Ribonucleic Acid 
NaCl- Sodium chloride  
NCAC- Non-Candida albicans Candida 
NCBI- National Center for Biotechnology Information 
ND- No Detected 
PBS- Phosphate Buffer Saline 
PCR- Polymerase Chain Reaction  
PLs- Phospholipases 
PNA–Peptide Nucleic Acid 
qRT-PCR- quantitative Real Time-Polymerase Chain Reaction 
RHOE- Reconstituted Human Oral Epithelium 
RHVE- Reconstituted Human Vaginal Epithelium 
RNA- Ribonucleic Acid 
Rev/min- Revolutions per minute 
RPMI- Roswell Park Memorial Institute media 
rRNA- ribosomal Ribonucleic Acid 
SAP- Secreted aspartly proteinase Candida albicans gene 
Sap- Secreted aspartly proteinase protein 
SAPP- Secreted aspartly proteinase Candida parapsilosis gene 
SAPT- Secreted aspartly proteinase Candida tropicalis gene 
SDA- Sabouraud Dextrose Agar 
Nomenclature 
 
 
xxxviii  
SDB- Sabouraud Dextrose Broth 
SEM- Scanning Electron Microscopy 
v- volume 
VC- Vaginal Candidosis 
w- weight 
YNB- Yeast Nitrogen Base 
  
 
 
 
Aim and Outline of the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Aim and Outline of the thesis 
 
xl  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim and Outline of the thesis 
 
 
xli  
Aim of the thesis 
The present research aims to provide significant insight into mechanisms of 
virulence, the importance of Candida species co-infection of vaginal epithelium and 
antimicrobial susceptibility of Candida species.  
Considering the relatively limited number of available antifungal agents and the 
increasingly apparent resistance of Candida to those that are available, it is essential to 
identify new and effective antifungal compounds.  
The first aim of this study was therefore to identify the antifungal potential of 
natural plants extracts, of flowers originating from the North Eastern of Portugal and also 
associated phenolic compounds. Antifungal screening was undertaken against planktonic 
and biofilms cells of Candida albicans, Candida glabrata, Candida parapsilosis and 
Candida tropicalis. 
Vaginal candidosis (VC) is a fungal infection mainly caused by the opportunistic 
pathogen, C. albicans. However, it is known that VC can involve more than one species, 
but interaction between these is poorly described. Consequently, the second goal of this 
research was to examine the interactions and expression of virulence factors by C. 
albicans and C. glabrata during mixed species infection. To achieve this, a reconstituted 
human vaginal epithelium (RHVE), based upon the A431 vaginal squamous cell carcinoma 
cell line was used to assess mechanisms of tissue degradation and virulence gene 
expression following infection with Candida species.  
Several in vivo environmental factors (e.g. hormone levels, pH, nutrient availability) 
may alter and facilitate transition of Candida from a harmless commensal to a pathogenic 
organism. Additionally, Candida species can rapidly respond to environmental changes 
and this flexibility may allow these organisms to take advantage of impaired immunity in 
debilitated patients and therefore facilitate establishment of disease. Therefore, as a final 
goal, the effect of progesterone on C. albicans biofilm formation and RHVE infection was 
evaluated.  
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Outline of the thesis  
The presented thesis reports research undertaken at CEB - Centre of Biological 
Engineering, University of Minho, Braga, Portugal, and at the Department of Tissue 
Engineering & Reparative Dentistry, School of Dentistry, Cardiff University, Cardiff CF4 
4XY, United Kingdom, under the supervision of Professor Mariana Henriques and 
Professor David W. Williams, respectively. 
This thesis is organised into five chapters: 
The first chapter is a general introduction that encompasses the current 
knowledge of Candida albicans and Non-Candida albicans Candida species in relation to 
taxonomy, epidemiology, virulence factors, antifungal resistance and methods of strain 
differentiation. A description of reconstituted human epithelium models used for 
demonstrating initial interactions of Candida species with human cells is also provided.  
In chapter two, research involving assessment of the antifungal potential of 
specific natural plant extracts and phenolic compounds identified in wild plants from North 
Eastern Portugal as new strategy against Candida resistant cells, is described. 
The third chapter addresses the determination of single and co-species 
colonisation and invasion of a reconstituted human vaginal epithelium (RHVE) model using 
C. albicans and C. glabrata strains. Expression of genes associated with Candida 
virulence, namely HWP1, ALS, EPA, PLB, and PLD are also investigated. 
The fourth chapter presents the effect of progesterone on C. albicans biofilm 
formation and RHVE infection, as well as, its influence in virulence gene expression.  
The fifth and last chapter covers the major conclusions of the thesis, suggesting 
some important issues that should be explored in future work.  
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1.1. Candida species 
1.1.1. Candida albicans and non-Candida albicans Candida species 
Of the fungi regarded as human pathogens, members of the genus Candida are 
the most frequently recovered from fungal infections and these Candida infections are 
collectively referred to as candidosis. The genus Candida is composed by an extremely 
heterogeneous group of over 150 species [1], but it is well established that only a few of 
these are implicated in human candidosis. Additionally, it is known that approximately 65% 
of the Candida species are unable to grow at a temperature of 37°C, and growth at this 
temperature is an important factor for an organism to be have pathogenic properties [1]. 
Of the Candida species isolated from humans, Candida albicans is the most prevalent 
(80% of isolates) in healthy and infected individuals [2–4], and this species is an 
endogenous commensal of the gastrointestinal and urogenital tracts [5].  
The prevalence of opportunistic fungal infections (candidosis) has dramatically 
increased over the recent decades and this is particularly evident in immunocompromised 
individuals [4]. Additionally, in recent decades, coupled with the improvements in the 
diagnostic methods and the emergence of molecular techniques, new Candida species 
(i.e. Non-Candida albicans Candida (NCAC) species) have been reported in human fungal 
infections, particularly Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida 
krusei, C. lusitaniae and C. dubliniensis [6–8].  
All species produce blastoconidia, which may be round or elongated yeast cells 
[9]. Most members of the genus also produce a filamentous type of growth, and these are 
typically pseudohyphae in NCAC, although C. albicans and C. dubliniensis can produce 
true hyphae. The difference between hyphae and pseudohyphae is related to the way they 
are formed (Figure 1.1). Pseudohyphae are formed from yeast cells or from hyphae by 
budding. This new structure remains attached to the parent cell and elongates, forming 
filaments with constrictions and without septa (internal cross walls). In the case of true 
hyphae, these filaments are formed from yeast cells or from hyphae branches. The 
development of true hyphae begins as outgrowths (germ tubes) from the yeast cell, 
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followed by elongation and branching of the filament. Septa are also created to provide 
structural support and compartmentalised sections within the hyphae of fungi [10,11].  
 
 
Figure 1.1 - The growth forms of Candida species: growth as yeasts (a), production of true hyphae (b) and 
pseudohyphae (c). Adapted from [11].
 
C. albicans and C. dubliniensis are considered polymorphic, due to their ability to form 
yeast, hyphae and pseudohyphae, and are also referred to as being germ tube positive [1]. 
However, C. glabrata is not polymorphic and grows only as blastoconidia (yeast). By this 
criterion, this species was only classified in the genus Candida in 1978, as it was only at 
this time that the ability to form pseudohyphae was recognised as not being a reliable 
distinguishing factor for members of genus Candida [12]. Compared with C. albicans, C. 
parapsilosis does not produce true hyphae, producing only pseudohyphae [9]. C. tropicalis 
can also produce oval blastospores, hyphae and pseudohyphae [1,9]. Yeast size should 
also be highlighted, as C. glabrata yeast (1-4 µm) are considerably smaller than C. 
albicans (4-6 µm), C. tropicalis (4-8 µm), and C. parapsilosis (2.5-4 µm) [11].  
In terms of biochemical characteristics of these species, it is important to note that 
C. albicans has the ability to ferment or assimilate a large group of sugars with the 
exception of sucrose, while the NCAC species ferment and assimilate specific sugars: 
glucose and trehalose, in the case of C. glabrata, and sucrose and maltose, for C. 
tropicalis. It is also described that C. parapsilosis does not have the ability to ferment 
maltose [13].  
Through genetic characterisation, differences between some NCAC species and C. 
albicans are clearly evident. Indeed, C. glabrata and C. lusitaniae are actually haploid 
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species, while C. albicans and several NCAC species e.g. C. dubliniensis, C. tropicalis and 
C. parapsilosis are diploid. It is also reported that C. tropicalis is more similar to C. 
albicans than C. glabrata [14].  
The different Candida species can also be easily distinguished by colony color on 
chromogenic agar medium (e.g. CHROMagar® Candida) [10]. Macroscopically, colonies 
of Candida species are cream colored to yellowish in Sabouraud’s Dextrose Agar (SDA). 
On CHROMagar® Candida (Figure 1.2), C. albicans produces light green colonies, C. 
tropicalis dark-blue colonies, C. glabrata white or pink-purple colonies, whereas C. 
parapsilosis produces cream coloured colonies [15]. 
 
 
Figure 1.2 - Colonies of Candida species grown for 48 h on CHROMagar®Candida at 37°C. Adapted from 
[16]. 
 
The cell wall of Candida species is an essential component of its success as a 
pathogen [17]. It is a dynamic and highly organized structure that determines both cell 
shape and viability, as well as providing a permeability barrier and determining the 
interaction between the microorganism and its environment [18]. The cell wall is required 
for growth, provides strength and protection against osmotic insult and might be 
considered an important factor in host tissue invasion and colonisation. The Candida cell 
wall is also the first point of contact with immune system of the host and therefore plays 
an important role in recognition and phagocytosis by host immune cells [18].  
C. tropicalis 
C. parapsilosis 
C
. a
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s C. glabrata 
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The C. albicans cell wall is mostly composed by polysaccharides (80%); with β-(1,3)-glucan 
covalently linked to β-(1,6)-glucan and chitin giving a robust external structure and scaffold 
for the glycoprotein layer (20%) (Figure 1.3). The glycoprotein layer comprised of 
remaining cell wall constituents including lipids, various inorganic salts and also many 
proteins (3.3-3.7%) and mannose (24.3-28.9%). These components are involved in 
permeability control, interaction with host cells, recognition of other fungi and regulation of 
several processes [19]. Than compared with C. albicans, C. glabrata cell wall has a higher 
quantity of proteins and mannose and a lower quantities of chitin and glucans [20].  
 
Figure 1.3 - Section of the C. albicans cell wall imaged by transmission electron microscopy and a schematic 
depiction of the arrangement of the major components of cell wall [21]. 
 
1.1.2. Health Associated Infections and Co-infections 
Candida species normally exist as commensals, but can also be opportunistic 
pathogens. Candida primarily causes superficial infections, affecting the oral and vaginal 
mucosa, but they can also be responsible for several systemic infections. The prevalence 
of opportunistic fungal infections has increased dramatically over recent decades and this 
is particularly evident in organ transplant recipients, patients with acquired immune 
deficiency syndrome (AIDS) and other immuno-compromising conditions, low-birth-weight 
newborns, critically ill patients requiring multiple catheters or patients with cancer [4]. 
Candida species now rank as the fourth most common causes of nosocomial infections in 
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the United States and the assigned mortality rate is 35%. Approximately 70% of women 
experience vaginal infections caused by Candida species and 20% suffer recurrence after 
treatment [22].  Invasive fungal infections, such as candidosis, is a major public health 
problem and are primary fungal infections encountered in immunocompromised patients 
undergoing prolonged hospitalization [23]. Candida are the fourth leading cause of 
nosocomial bloodstream infection, with an attributable mortality rate of about 40% [4]. In 
the case of vaginal Candida, colonisation rates again vary with studied groups, with rates 
of 41% and 21% reportedly occurring in type 1 and type 2 diabetic patients, respectively 
[24]. Pregnant women are also reported to have a high incidence of vaginal candidal 
carriage [25], and vaginal candidosis is one of the most common superficial infections in 
reproductive age women [26]. 
Although most cases of candidosis have been attributed to C. albicans, more 
recently NCAC species have been identified as common pathogens. The prevalence of 
these species in human infection has been changing in recent years. In European 
countries, analysis has showed that the incidence rates of candidosis caused by NCAC 
species were 14% each for C. glabrata and C. parapsilosis, 7% for C. tropicalis and 2% for 
C. krusei [27]. C. tropicalis has emerged as the second or third most common agent of 
candidosis, mainly in nosocomial urinary tract infections [28]. C. parapsilosis, although 
generally regarded as one of the less virulent Candida species, is now attributed to 
infection following its transfer via the hands of healthcare workers [29]. C. glabrata, the 
newest recognised nosocomial Candida pathogen, has particular importance because of 
its naturally high resistance to certain antifungal agents, specifically the azoles [30].  
Nowadays, several studies have reported enhanced Candida species epithelium 
invasion/colonisation and candidosis episodes caused by co-infection (two or more 
Candida species combined or associated to other species). Enhanced C. albicans 
colonisation and invasiveness of C. glabrata and led to increased damage in the 
reconstituted human oral epithelium [31]. In 2013, Kali et al. [32] showed that Candida 
species were emerging as a potentially pathogenic fungus in patients with broncho-
pulmonary diseases, and demonstrated synergistic growth promoting association of 
Candida species and Mycobacterium tuberculosis in 40% of patients with pulmonary 
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tuberculosis. In 2010, Martins et al. [33] described Candida species oral co-infection 
episodes in patients attending a dental clinic in Braga, Portugal, where the combination of 
C. albicans - C. glabrata was the most commonly found, as noted in other studies [34–
38]. 
Fungal endocarditis is an uncommon complication of invasive candidal infection, 
but there is an increasing incidence over the last 15 years [39,40]. Neonatal endocarditis 
caused by Candida is associated with high mortality and morbility [41]. Successful 
treatment often requires prolonged systemic antifungal therapy as well as surgical 
intervention [42]. Some cases of endocarditis had been identified in drug abusers due to 
co-infection between C. albicans and C. tropicalis [43]. In 2009, Daas et al. [44] reported 
an endocarditis episode caused by the combination of C. parapsilosis and P. aeruginosa. 
1.1.3. Virulence Factors 
Virulence factors are all aspects associated with metabolic pathways that directly 
interact with the host tissue causing damage and infection. There are several lines of 
argument for what is true virulence factors are generated by Candida species. Viruelence 
factors have been described as: “all traits required to establish disease” [45], “factors that 
interact directly with mammalian host cells” [46] and “a component of a pathogen that 
damages the host” [47]. In order to establish an infection, opportunistic pathogens have to 
evade the immune system, survive and divide in the host environment and spread to the 
new tissue.  
Virulence factors of Candida species include the ability to: (I) undergo polymorphism, (II) 
adhere to biotic or abiotic surfaces, (III) secrete hydrolytic enzymes and (IV) form biofilms. 
I- Polymorphism 
A reversible morphologic transition (Figure 1.1) between unicellular yeast cells and 
filamentous phase (hyphae and pseudohyphae) is an important virulence factor of some 
Candida species as described above. This ability provides cells with the flexibility of being 
able to adapt to hostile conditions imposed by the human body [17]. The filamentous 
phase is constituted by a cell wall, which contains three times more chitin than the yeast 
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form. This composition increases its resistance to phagocytosis, gives more mechanical 
strength allowing enhanced epithelium colonisation and invasion into epithelial layers of 
tissues [17,48]. Furthermore, there is evidence that the yeast-hyphal switch is affected by 
temperature, pH (see section 1.2) and other virulence factors described in detail bellow. 
For instance, expression of secreted aspartyl proteinase (SAPs4-6) genes occur specifically 
during hyphal development [49]. Moreover, Hube et al., 2001 [50] showed that 
phospholipases D (PLD1) is necessary for yeast-to-hyphal transition by Candida albicans. 
 
II- Adherence to biotic or abiotic surfaces 
Adherence of Candida to host cells or abiotic surfaces is seen as an essential early 
step in the establishment of disease [10]. This adhesion is dependent on several factors 
such as the presence of cell wall proteins, that are recognized by receptors (e.g. 
fibronectin, fibrinogen and vitronectin) present on epithelial, endothelial and foreign-body 
surfaces, and cell surface physicochemical properties [51]. As surfaces of Candida and 
epithelial cells are generally negatively charged establishment of a successful adherence 
is, in part, dependent on the sum of non-specific factors contributing to the total free 
energy of interaction. These include attractive Lifshitz-van der Waals forces, hydrophobic 
interaction and Brownian movement, as well as the repulsive effects of the electrical 
double layer of cells [52].  
Host cell recognition and colonisation by Candida species is facilitated by several 
adhesins (Table 1.1) that bind specifically to peptides or sugar residues of other cells 
and/or increase the cell surface hydrophobicity, promoting the binding to abiotic surfaces 
through hydrophobic interactions [53].  
Adhesins on the cell surface of C. albicans can interact with serum proteins, 
components of the extracellular matrix (ECM) of host tissues and immobilised ligands such 
as cadherins or integrins [54]. An important serum component that C. albicans can bind 
to is Factor H (FH) [55] which is a key regulator of the alternative pathway (AP) of 
complement, and incorporation of FH on the surface of C. albicans prevents AP activation 
[56]. Laminin, fibronectin, collagen, entactin, vitronectin and tenascin are all ECM proteins 
that C. albicans can interact with [57]. 
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Table 1.1 - Examples of Candida albicans adhesins and associated host cell ligands [58] 
 
Candida adhesin Host cell receptor 
Integrin analog [59–61] iC3b, Arginine-glycine-aspartic acid 
Fibronectin adhesin [62–64] Fibronectin and vitronectin receptors 
Fucoside binding adhesin [65–67] glycoside (glycoprotein or glycolipid) receptor 
GlcNAc-binding protein [66,67] N-Acetylglucosamine 
Fimbrial adhesin [68] GalNAc(1-4-Gal) 
Hyphal Wall Protein 1 [69,70] 
Covalently linked to cell wall 1,6-glucan through a remnant 
of its glycosylphosphatidylinositol (GPI) anchor 
Agglutinin-like Sequence family 
[71–73] 
Linked to 1,6-glucan and behave as a GPI module 
Enhanced Adherence to 
Polystyrene [74] 
GPI-attached site ω and a valine at the ω-5 site 
 
Members of the agglutinin-like sequence (ALS) gene family of C. albicans encode 
for large cell-wall glycoproteins, some of which are implicated in the adhesion of the 
organism to host surfaces [75,76]. The ALS gene family comprises 8 members (ALS1-7,9) 
and all have a similar three-domain structure and are associated with the β-1,6 glucan of 
the cell wall of C. albicans [72]. Hyphal wall protein 1 (HWP) is another protein involved in 
C. albicans adhesion to epithelial cells and this protein is perhaps the most widely studied 
adhesin of C. albicans [77]. Glutamine residues in the N-terminal domain of HWP1 can be 
cross-linked to unidentified host proteins by host transglutaminase activity and this leads to 
covalent attachment of the yeast to host epithelial cells. Recently, the gene encoding for C. 
albicans EAP1 was identified. This gene was originally investigated because of its ability to 
encode for a protein mediating adhesion to polystyrene of a Saccharomyces cerevisiae 
flocculin-deficient strain. EAP1 encodes for a glycosylphosphatidylinositol-anchored, 
glucan-cross-linked cell wall protein that has, since then, been shown to facilitate adhesion 
of C. albicans to epithelial cells as well as polystyrene [54]. After adherence to surfaces 
has been established, colonisation and growth of C. albicans is essential to sustain the 
presence of the organism at the host site. 
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The in vitro adherence of C. glabrata to epithelial cells is mediated by EPA genes, of which, 
up to 23 different genes have already identified, although the function of the majority is 
only partially understood [78]. There are few studies about Epa proteins, but it is already 
known that EPA1 encodes a lectin that recognizes host N-acetyl lactosamine containing 
glycoconjugates and this confers adhesion of fungal cells to mammalian surfaces. There is 
relatively limited information about the adhesins of NCAC species. However, Panagoda et 
al., 2001 [79] showed that the initial adhesion of C. parapsilosis was associated with 
surface hydrophobicity. The same study comparing C. albicans and C. parapsilosis 
adhesion reported a greater ability (21%) of C. parapsilosis to adhere to buccal epithelial 
cells with an increase of 14% in the extent of adhesion to acrylic. Looking to proteins from 
C. tropicalis cell wall, at least 3 ALS genes were identified through Southern and Western 
blotting analysis with anti-Als antibody [76]. However, no further work has been 
undertaken in this area.  
III- Secretion of hydrolytic enzymes 
The production and release of hydrolytic enzymes by extracellular secretion, are 
also key factors of Candida virulence [17,80]. These enzymes help mediate host adhesion, 
tissue invasion and destruction, and are also thought to be responsible for modulating host 
immune responses [17]. The most discussed hydrolytic enzymes released during the 
pathogenic process are secreted aspartic proteinases (SAPs), but phospholipases, 
hemolysins and lipases are also involved in Candida virulence [80].  
The SAP family of C. albicans is currently known to comprise 10 genes encoding 
for proteinases with masses of 35 to 50 kDa. SAPs1-3 and SAPs4-6 are thought to 
represent two subfamilies [81]. Studies have demonstrated that C. albicans, C. 
parapsilosis and C. tropicalis are good producers of Saps [10,82,83]. Gene expression of 
SAPs1-6, appears to be related to adherence, tissue damage, and changes in the immune 
response [81,84,85]. SAPs4-6 are expressed by C. albicans during hyphal invasion of a 
reconstituted human oral epithelium, oral infection [86] and are linked with hyphal 
formation and invasion of the epithelium [81] and apoptosis of epithelial cells [87]. In the 
case of C. parapsilosis, three genes have been identified (SAPP1-3), but two of these 
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remain uncharacterized. In addition, C. tropicalis SAPs are encoded by four genes (SAPT1-
4), but only SAPT1 has been characterized. Only one study has been done that 
demonstrates an ability of C. glabrata to produces proteinase, but the proteinase type 
remain unknown [10].  
In addition to SAPs, C. albicans has two other hydrolytic gene families, namely the lipases 
(LIP) and phospholipases (PL), and these are associated with candidal adhesion, nutrient 
acquisition and invasion of epithelial surfaces [88].  
The LIP gene family of C. albicans comprises of at least 10 genes (LIP1-10) [89], whilst 7 
phospholipase genes of C. albicans have been reported (PLA, PLB1-2, PLC1-3, and PLD1) 
[90]. LIPs are involved in the hydrolysis and synthesis of triacylglycerols and are 
characterised by having stability at high temperatures and in organic solvents, and being 
resistant to proteolysis [91]. It is important to emphasize that the role of PLs is to 
hydrolyse ester bonds in glycerophospholipids and this causes host cell membrane 
damage, facilitating invasion of host tissues by the exposure of receptors to adhesions. 
PLB1 is proposed  to have an important role in the secretion of phospholipase B by C. 
albicans [83]. NCAC species also produce extracellular PLs, but in lower amounts than C. 
albicans [10].  
Hemolysins are enzymes that induce the rupture of hemoglobin, leading to release 
of elemental iron from host cells [10,92]. Although essential for growth of Candida, free 
iron sources are very limited in the body as most iron is appropriated by host proteins, 
especially transferrin [93]. Thus, hemolysins secreted by Candida serve to replenish the 
organisms' supply of iron from hemoglobin. A variety of Candida species produce α or β 
hemolysin, with C. albicans and C. dubliniensis being the greatest producers, and 
production may increase in the presence of elevated blood glucose concentrations [94–
96]. The putative gene involved in expression of Candida hemolysin is HLP (Haemolysin 
Like Protein) [10,92]. 
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IV- Candida Biofilms 
One of the major contributions to Candida species virulence is its versatility to 
adapt to a variety of different habitats and the formation of surface-attached microbial 
communities known as biofilms (Figure 1.4) [97,98].  
 
 
Figure 1.4 - Schematic of biofilm formation on a polyvinylchloride catheter surface. (a) Catheter surface with 
an adsorbed conditioning film of host proteins (black dots). (b) Initial yeast cell (red) adhesion to surface. (c) 
formation of basal microcolony layers of microorganisms. These anchor each microcolony to the surface. (d) 
completion of microcolony formation by addition of the upper, mainly hyphal layer and matrix material 
(yellow) that surrounds both yeasts (red) and hyphae (green). Mature biofilms contain numerous 
microcolonies with interspersed water channels to allow circulation of nutrients. (e) Cells released or 
detached from the biofilm spread into the environment, dispersing infections and forming new biofilms. 
Adapted from [98]. 
 
Biofilm formation (Figure 1.4) begins with the attachment of free-floating cells to a 
surface. These first cells initially adhere weakly and reversibly to the surface via Van der 
Waals forces. Some microorganisms are not able to attach to a surface on their own, but 
are able to anchor themselves to the matrix or directly to other earlier colonising 
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microorganisms. Once colonisation has begun, the biofilm grows through a combination of 
cell division and recruitment. In the maturation step, the biofilm is established and may 
change only in shape and size. The final step is dispersion, where cells detach from the 
biofilm and start to spread and colonise new surfaces.  
In most natural environments, microorganisms exist predominantly as biofilms rather than 
as planktonic or free-floating cells. Biofilms represent structured microbial communities 
that are attached to a surface, where the individual microorganisms are embedded within 
a matrix of extracellular polymeric substances (EPS) [99].  
Generally, in addition to water, the composition of EPS includes, carbohydrates, proteins, 
minerals, hexosamines and extracellular DNA. However, a large portion of the biofilm 
matrix still remains to be identified [100].  
Microorganisms that live in a biofilm have significantly different properties than free-floating 
(planktonic) microorganisms, as the presence of the matrix, protects embedded biofilm 
cells. In addition, the microenvironment formed may allows the establishment of symbiotic 
microbial associations that can provide essential nutrients to some species. The close 
contact between cells of different species/strains favors the transmission of mobile genetic 
elements [101].  
Both commensal and pathogenic organisms can form biofilms in human tissues 
and around 60-65% of microbial infections are thought to have a biofilm origin [102]. 
Although multi-species biofilms are most commonly encountered, single-species biofilms 
are also evident in some infectious diseases [103].  
Microbial biofilms are notoriously resistant to a variety of antimicrobial agents, 
including antibiotics/antifungal, antiseptics, host defence molecules and industrial 
biocides. Susceptibility studies have revealed that biofilms formed by C. albicans may be 
up to 100-fold more resistant to antifungal drugs than planktonic cells [100,104,105].   
Candida species can adhere and form biofilms on natural host surfaces or on 
biomaterials of medical devices [106]. The overall organization of a Candida biofilm is 
generally similar to a bacterial one, but its structural details are highly dependent upon the 
conditions under which the biofilm formed. Numerous experimental parameters, such as 
the surface material, medium and conditions of incubation will influence the biofilm 
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structure and the morphology of its cells [107]. The formation of Candida biofilms has 
important clinical repercussions because it provides a considerable resistance to antifungal 
therapy by limiting the penetration of these substances through the matrix and the 
protection afforded against host immune defenses [99,108]. 
1.1.4. Antifungal Resistance 
Since their discovery during the 20th century, antimicrobial agents have 
substantially reduced the risk posed by infectious diseases. The use of these 
antimicrobials, combined with improvement in nutrition and the implementation 
immunization programs, has led to a notable drop in deaths from infectious diseases. 
Although antimicrobials have saved the lives of millions of people, in the recent years the 
advantages of these drugs has been compromised with the appearance of resistant 
microorganisms. When infections are caused by resistant microorganisms, treatment has 
to be switched to second- or third-line drugs, which are usually more expensive and 
occasionally more toxic.  
Candidosis can be treated using several classes of drug (azoles, candins or 
polyenes). The choice of the agent depends on the local epidemiology and the origin of the 
infection [109]. The cost of a candidosis episode has been estimated at $44 000 for 
adults and $28 000 for neonates [110,111]. However, a four-fold increase in hospital 
spend on antifungals has been recognised, which is not accounted for solely by increases 
in the number of fungal infections. An abrupt change in the way drugs are prescribed and 
the use of newer antifungal drugs, sometimes in combination therapies, are part of the 
problem. At least 70% of the antifungal drugs prescribed are part of an empirical strategy 
[112]. In addition, the emergence of NCAC species in infection has been an issue as these 
tend to be inherently less susceptible to the available antifungal drugs like the azoles and 
their derivatives, which are frequently the antifungal agents of choice against candidosis 
[113,114].  For example, since the introduction of fluconazole in 1990 for the treatment of 
candidosis, empirical antifungal therapy has been driven by fear of infections caused by C. 
glabrata as this species exhibits reduced susceptibility to fluconazole and cross-resistance 
to other azoles [115].  
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Increased resistance to antifungal agents is one of the defining characteristics of 
biofilms [116]. Over the recent years, several factors that play a role in fungal biofilm 
resistance have been described, including the altered physiological state, cell density, 
extracellular polymeric substances, efflux pump-mediated resistance, overexpression of 
drug targets and the presence of persister cells [17,116]. In biofilms, nutrient and oxygen 
limitation are responsible for slowing down the growth rate and activity of cells embedded 
in the biofilm. This effect would render agents active against the cell division process less 
effective and also result in a slower or inefficient drug uptake [98,99,117]. Furthermore, 
other factors like pH, temperature, changes in osmolarity and ionic stress can also effect 
conserved signaling pathways and perhaps alter antifungal susceptibility, which suggests 
that more complex factors may be involved in drug resistance of biofilms [118,119]. For 
example, C. albicans biofilms show an increased resistance to a wide range of 
conventional antifungal agents, such as amphotericin B and fluconazole. The biofilm 
phenotype can be about twenty times more resistant to amphotericin B and one hundred 
times more resistant to fluconazole compared with the planktonic growth form [105,120].  
Gathering together the inherent resistance of Candida species and the difficulty in biofilm 
treatment, there is a clear necessity to develop new alternative antifungal agents, in order 
to increase the spectrum of activity against Candida species. To partly address this, there 
has recently been an increased interest in natural phytochemicals derived from fruits, 
vegetables, plants and herbs that have been reported to possess a wide range of biological 
effects, including antioxidant, antimicrobial and anti-inflammatory actions [121]. Essential 
oils and their main components have many applications in popular medicine, food, 
beverages, preservation, cosmetics as well as in the fragrance and pharmaceutical 
industries [122]. Essential oils are mixtures of compounds obtained from spices, aromatic 
herbs, fruits, and flowers and characterised by their aroma [123]. The antimicrobial 
properties of essential oils have been known for a long time, and various research has 
been conducted into their antimicrobial activities against various bacteria and fungi [124]. 
Furthermore, in recent years, interest in phenolic compounds has also raised. Such 
compounds include phenolic acids and flavonoids that have been reported to inhibit 
various pathogenic bacteria and fungi [125–127]. In 2011, Barros et al. [128] highlighted 
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the importance of wild plants as sources of phenolic compounds, such as phenolic acids, 
flavonoids and anthocyanins and several studies have reported the effectiveness of these 
phenolic compounds in the inhibition of various pathogenic bacteria and fungi 
[125,126,129–131].  
1.2. Environmental factors 
Effective responses to environmental changes are fundamental for the survival of 
microorganisms. Environmental adaptation is particularly relevant for pathogens, which 
must counteract the defence systems of their host as well as tune their metabolism and 
stress homeostatic mechanisms to the complex microenvironments they encounter. 
Different environmental factors, such as temperature, pH, glucose, hormones, can 
influence the normal growth, infection and pathogenicity of Candida species 
[105,132,133].  
Although the parameters that triggers morphologic Candida dimorphism are not yet well 
understood, in vitro studies have shown that this behaviour is influenced by temperature 
and pH. Unicellular yeast phase growth is stimulated at 25°C and acidic pH, whereas 
filamentous growth is favoured at 37°C and with a neutral pH [84]. These changes are 
often mediated by cell surface receptors that initiate signal transduction cascades resulting 
in altered activity of transcription factors and thus modification of gene expression. 
Variation in pH can also influence Candida gene expression. In 2001, Lane et al. [134] 
showed that altered pH effects expression of virulence factors including the SAPs. Glucose 
plays a central role as a carbon and energy source and glucose sensing and response is 
therefore highly involved and closely regulated in most organisms. The importance of 
glucose to yeast cells is highlighted by the large number of hexose transporters they 
possess. Saccharomyces cerevisiae has at least 17 different hexose transporters that are 
expressed under different conditions, whilst C. albicans appears to have over 20 [135].  
In 2012, Silva et al. [10] showed that biofilms were readily formed by C. parapsilosis 
grown in media containing higher glucose. Furthermore, the production of Candida 
haemolytic factor may be regulated by the presence of glucose in the growth medium.  
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As stated above, vaginal candidosis (VC) is an opportunistic infection caused by Candida 
species that affects healthy women. Several episodes of VC frequently occur during 
pregnancy and the luteal phase of the menstrual cycle, when the levels of progesterone 
and estrogen are elevated [136]. The same study [136] showed that progesterone has no 
effect on VC in mice, but an excess of estrogen promoted Candida growth. They also found 
that the excess estrogen reduces the ability of skin cells to prevent colonisation of Candida 
on the vaginal walls. Furthermore, it is known that in the absence of estrogen treatments, 
VC is short-lived, with a low fungal burden in the vagina [137]. 
1.3. Reconstituted human epithelium 
Oral and vaginal epithelia are complex multi-layered, multi-cellular tissues 
consisting of increasingly differentiated epithelial cells. As a consequence the use of 
monolayer cultures in vitro infection studies are unlikely to be representative [138,139].  
Several model systems have been used to study Candida-host interactions. Murine 
models and in vitro monolayer cultures have generated some data on the likely virulence 
and host factors that contribute to the development of candidosis [140]. Murine models of 
oral candidosis have been used to identify several potential virulence factors that may play 
a role in pathogenesis [141,142], but since C. albicans does not naturally colonise the oral 
cavity of mice it is not clear how representative these studies are. Furthermore, mouse 
models do not completely mimic human candidosis as there are significant differences 
between the immune systems of humans and mice [143], which may make results 
difficult to interpret. There are also ethical restraints relating to experiments involving 
animals.  
Recently multi-layered organotypic three-dimensional in vitro culture systems have 
been developed to mimic various epithelia. The in vitro reconstructed human epidermis 
(SkinEthic Laboratories, Nice, France) consists of normal human keratinocytes cultured on 
an inert polycarbonate filter at the air-liquid interface, in a chemically defined medium. 
These models are histologically similar to those of the in vivo human epidermis but do lack 
a keratinised surface layer and stratum corneum (Figure 1.5).  
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Figure 1.5 - SkinEthic Human Epithelium (RHE). (a) oral mucosa epithelium in vivo, (b) reconstituted human 
oral epithelium in vitro, (c) vaginal mucosa epithelium in vivo and (d) reconstituted human vaginal epithelium 
in vitro. Adapted from [144,145].
 
 
The reconstituted human oral epithelium (RHOE) (Figure 1.5 b) and reconstituted 
human vaginal epithelium (RHVE) (Figure 1.5 d), based upon the TR146 buccal carcinoma 
cell line and the A431 vaginal squamous cell carcinoma cell line, respectively, are effective 
for modeling the initial interactions of Candida species with human cells [31,146–149]. 
These models require at least 3 days to be established and can be maintained thereafter 
for 2-4 days. In these models, experiments of infection are highly reproducible 
[31,147,150]. These models can be used for the direct analysis of pathogen-epithelial cell 
interactions, the evaluation of the host immune response, to investigate cellular 
interactions or protein and gene expression. It is also possible to study the impact of 
innate immunity or the antifungal activity of natural and non-natural compounds [148].  
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Abstract 
Life-threatening mycoses caused by opportunistic fungal pathogens (mainly species 
from the genus Candida) are frequently encountered as nosocomial infections, and currently 
represent a major health challenge. Given the relatively limited number of available 
antifungal agents and the increasingly apparent resistance evident with those that are 
available, it is essential to identify new antifungal compounds. Of particular interest are 
those derived from natural sources and these agents frequently exhibit a wide activity 
spectrum against Candida species with little resistance. In this chapter, the antifungal 
potential of natural plants extracts (Castanea sativa, Filipendula ulmaria, Rosa micrantha 
and Cistus ladanifer) and of four phenolic compounds (gallic acid, catechin, luteolin and 
quercetin) was screened. All of these agents originate from wild plants located in North 
Eastern Portugal and tests were undertaken using planktonic cells and biofilms of Candida 
albicans ATCC 90028, Candida glabrata ATCC 2001, Candida parapsilosis ATCC 22019 
and Candida tropicalis ATCC 750.  
The minimal inhibitory concentrations (MIC) of plant extracts and phenolic 
compounds were determined against Candida planktonic cells and the effect of phenolic 
compounds on Candida biofilms was assessed by quantification of colony forming units 
(CFUs). 
Overall, the highest antifungal effect against all the Candida species was showed by 
the extract from Rosa micrantha (MIC ≤ 0.156 mg/ml). Results using phenolic compounds 
showed that gallic acid had the highest mg/ml effect against the four Candida species in 
planktonic form (MIC ≤ 0.156 mg/ml). Catechin showed a similar effect against C. albicans 
cells. Additionally, gallic acid and quercetin demonstrated only a slight effect against 
Candida species biofilms. 
Chapter II 
32  
2.1. Introduction 
The genus Candida is composed of an extremely heterogeneous group of over 150 
species [1], and it is well established that a minority of these are implicated in human 
candidosis [1,2]. 
A major virulence factor of Candida is its ability to adapt to a variety of different 
habitats and the subsequent formation of surface-attached microbial communities known 
as biofilms [3–5]. Candida yeast within a biofilm can have significantly different properties 
from ‘free-floating’ or planktonic microorganisms, due to the existence of extracellular 
polymeric substances (EPS) surrounding them. The physical structure and chemical 
composition of a biofilm is largely determined by the EPS and allows different 
microorganisms to cooperate and interact in various ways. Importantly, the presence of 
EPS confers a certain degree of protection against host defence molecules and cells as 
well as administered antimicrobial agents.  Of note is that candidal biofilm communities 
reportedly present elevated tolerance to typical antifungal drugs, like amphotericin B and 
fluconazole [6,7]. 
Biofilms can be found on different surfaces including those that are biotic 
(mucosal surfaces) and abiotic (invasive medical devices) [8,9]. The biomedical 
significance of these biofilms is considerable, as most hospital infections have origins 
within preformed biofilms [10,11]. 
Currently, it is widely acknowledged that Candida albicans and, recently, non-
Candida albicans Candida (NCAC) species exhibit high levels of resistance to antifungal 
therapies such as the azole drugs and their derivatives, which continue to be the empirical 
treatment of choice for Candida-related infections [12–15]. In addition candidosis can be 
treated with echinocandins and polyene antifungal classes. The selection of the antifungal 
agent depends on the epidemiology local, the percentage of resistant strains to fluconazole 
and even the origin of the infection [16]. Additionally, at least 70% of the antifungal drugs 
are prescribed empirically [17] and consequently it has been noted a decreased in 
susceptibility to fluconazole and cross-resistance to other azoles.  
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Thus, in order to overcome this clinical problem, an enlarged interest to find new 
effective natural drugs, such as plant extracts compounds (specifically some phenolic 
compounds) and essential oils, has been observed [18–20].  
In this context, the main objective of the present work was to evaluate the 
antifungal potential effect of four plant extracts from the North Eastern of Portugal, 
Castanea sativa, Filipendula ulmaria, Rosa micrantha and Cistus ladanifer, and four 
phenolic compounds, gallic acid, catechin, luteolin and quercetin identified in those plants 
against Candida planktonic and biofilm cells (C. albicans ATCC 90028, C. glabrata ATCC 
2001, C. parapsilosis ATCC 22019 and C. tropicalis ATCC 750). 
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2.2. Material and methods  
2.2.1. Preparation of plant extracts 
Plants extracts were collected from Castanea sativa, Filipendula ulmaria, Rosa 
micrantha [21] (flowers extracts) and Cistus ladanifer [22] (fresh leaves extract) originating 
in the Natural Park of Montesinho territory, Trás-os-Montes, North Eastern Portugal. 
Extracts were obtained according to local medicinal criteria of use and each plant growth 
pattern. Extracts were lyophilized (Ly-8-FM-ULE, Netherlands) and stored at -20°C for 
subsequent analysis. The procedure described below was done by the colleagues from 
CIMO/Escola Superior Agrária, Instituto Politécnico de Bragança, Bragança, Portugal 
[21,22]. Briefly, extracts were obtained by treating each plant sample (1 g) with 30 ml of 
methanol:water 80:20 (v:v) at room temperature, 150 rev/min, for 1 h. The extract was 
filtered through Whatman number 4 paper. The residue was then re-extracted twice, with 
additional 30 ml portions of methanol:water 80:20 (v:v). The combined extracts were 
evaporated at 35°C (Rotary Evaporator Büchi R-210) to remove methanol. The aqueous 
phase was lyophilized and re-dissolved in distilled water at 200 mg/ml for antifungal 
assays or in 20% aqueous methanol at 5 mg/ml and filtered through a 0.22 µm 
disposable LC filter disk for High Performance Liquid Chromatography (HPLC) analysis.  
2.2.2. Preparation of phenolic compounds 
The extraction, identification and quantification of phenolic compounds from 
flowers of Castanea sativa, Filipendula ulmaria, Rosa micrantha [21], Cytisus multiflorus 
[23] and fresh leaves of Cistus ladanifer [22] was previously described by Barros el al. 
[21–23] using HPLC-DAD/ESI-MS. Eight different phenolic compounds were highlighted as 
being the main compounds; three phenolic acids: caffeic acid (Caf), ellagic acid (Ell), gallic 
acid (Ga); and five flavonoids: apigenin (Api), catechin (Ca), kaempferol (Kae), luteolin (Lu) 
and quercetin (Quer).  
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2.2.3. Candida strains 
Four Candida reference strains from the American Type Culture Collection (ATCC), 
namely Candida albicans (ATCC 90028), Candida glabrata (ATCC 2001), Candida 
parapsilosis (ATCC 22019) and Candida tropicalis (ATCC 750) were used in this study.  
2.2.4. Minimal inhibitory concentration determination 
Prior to undertaking antifungal assessment experiments for the plant 
extracts/phenolic compounds activity experiment, all reference species were cultured on 
Sabouraud Dextrose Agar (SDA; Merck, Germany) for 24 h at 37°C. 
For antifungal assessment of plant extracts, at least five colonies (1 mm diameter) of each 
Candida species were suspended in 5 ml of sterile saline solution (0.85% of NaCl in water) 
and the resulting yeast suspension vortex mixed for 15 s. The suspensions were then 
adjusted by spectrophotometric method, adding saline solution to reach the value of 0.5 in 
the McFarland scale corresponding to a final concentration of 3.0 ± 2.0 × 106 cells/ml.  
In the case of antifungal phenolic compounds activity, Candida were cultured in Sabouraud 
Dextrose Broth (SDB; Merck, Germany) for 18 h at 37°C under agitation at 120 rev/min. 
After incubation, the cells were harvested by centrifugation at 3000 g for 10 min at 4°C 
and washed twice using 15 ml of phosphate buffer saline (PBS; pH 7, 0.1 M). Pellets 
formed were suspended in 10 ml RPMI 1640 medium (Sigma, St Louis, USA), buffered to 
pH 7 and the cellular density adjusted to 2x107 cells/ml using a Neubauer 
haemocytometer (Marienfild, Land-Könicshofen, Germany). It should be pointed out that 
this cell concentration was different from the one used with the extracts, since it was 
intended to test this compounds also against biofilms, and therefore, cell inoculum 
concentration was adjusted.  
The Minimum Inhibitory Concentration (MIC) of the agents against all the species 
under study, was determined according to the guidelines described by the National 
Committee for Clinical Laboratory Standards (NCCLS) [24], with some modifications. 
Initially, serial dilutions of each plant extract and phenolic compound were prepared in 
RPMI 1640 medium to provide concentrations ranging from 0.05 to 5 mg/ml and 0.156 
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to 1.25 mg/ml, respectively. These concentrations were stored at -20°C until used in the 
assay. Volumes of each plant extract/phenolic compound (100 µl), at a two-fold final 
concentration together with 100 µl of Candida suspension were mixed in the wells of 
microtitre plate (Orange Scientific, Braine-l’ Alleud, Belgium). The 96-well plates were 
incubated at 37°C for 48 h and the MIC determined by direct observation and by 
determination of the number of colony forming units (CFUs). CFUs were determined after 
appropriate serial dilutions of the well contents in PBS and by plating 10 µl of each cell 
dilution on to SDA. After 24 h incubation at 37°C, the number of the colonies was 
counted. Experiments were performed on three separate occasions and in each 
experiment at least triplicate samples were tested. Yeast culture without test agent and 
RPMI without Candida were included as controls. 
2.2.5. Antibiofilm activity of phenolic compounds on Candida biofilms 
Standardised Candida cell suspensions (200 µl containing 1x107 cells/ml in RPMI 
1640 medium) were placed into the wells of 96-well microtitre plates (Orange Scientific, 
Braine-l`Alleud, Belgium) and incubated at 37°C on a shaker at 120 rev/min for 24 h. 
Negative controls (200 µl of RPMI 1640 medium devoid of Candida) were also included. 
After 24 h, the culture medium was aspirated and non-adherent cells removed by washing 
the biofilms once in 200 µl of PBS. Then, 200 µl of each phenolic compound (prepared in 
RPMI 1640 medium; concentration range 0.625 to 5 mg/ml) was added to each well. The 
biofilms were incubated for further 24 h at 37°C on a shaker at 120 rev/min. The effect of 
the phenolic compounds on Candida biofilms was then assessed by quantification of the 
number of CFUs. To determine this, culture medium containing test agent was removed 
and the biofilms washed once with 200 µl of PBS.  
The biofilms resuspended in 200 µl of PBS were removed from the wells by physically 
scraping the respective wells. The recovered biofilm suspension was vigorously vortexed 
for approximately 2 min to disaggregate cells. Serial dilutions were then prepared in PBS, 
and these were cultured on SDA for 24 h at 37°C. Experiments were performed in 
triplicate and in at least three independent assays.  
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2.3. Results and Discussion 
2.3.1. Antifungal activity of the plant extracts 
In recent years, an increasing number of Candida species that are resistant to the 
commonly used antifungal agents has become evident [25]. In order to overcome this 
problem, the identification of new antifungal compounds is highly important. Particular 
focus has been directed to naturally derived compounds such as those evident in plant 
extracts. Often, these agents exhibit antimicrobial effects against a wide range of 
microorganisms with little or no resistance being evident.  
In this study, the aim was to examine for the first time, the antifungal effect of 
extracted compounds from the Portuguese indigenous plants Castanea sativa, Filipendula 
ulmaria, Rosa micrantha (flowers extracts) and Cistus ladanifer (fresh leaves extract). The 
minimum inhibitory concentration (MIC) values against four different species ranged from 
0.05 to 0.625 mg/ml depending on agent were present in Table 2.1. Furthermore, it is 
important to highlight that the extracts presented different activities against the different 
Candida species under study. 
 
Table 2.1 – Minimum inhibitory concentrations (MIC; mg/ml) of wild plant extracts against Candida species 
 
 MIC (mg/ml) 
 
C. albicans 
ATCC 90028 
C. glabrata 
ATCC 2001 
C. parapsilosis 
ATCC 22019 
C. tropicalis 
ATCC 750 
Castanea sativa 0.625 < 0.05 < 0.05 0.625 
Filipendula ulmaria 0.625 < 0.05 < 0.05 0.156 
Rosa micrantha 0.05 < 0.05 < 0.05 0.156 
Cistus ladanifer < 0.05 < 0.05 < 0.05 0.625 
 
In 2001, Aligiannis et al. [26] proposed a classification for plant extracts, based on 
the MIC values obtained for C. albicans and this defined strong inhibitors (MIC up to 0.5 
mg/ml), moderate inhibitors (MIC between 0.6 and 1.5 mg/ml) and weak inhibitors (MIC 
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above 1.6 mg/ml). According to this classification and the values present in Table 2.1, the 
extract of C. sativa extract presented moderate activity (MIC = 0.625 mg/ml) against C. 
albicans ATCC 90028 and C. tropicalis ATCC 750, but a strong activity (MIC < 0.05 
mg/ml) against C. glabrata ATCC 2001 and C. parapsilosis ATCC 22019. F. ulmaria 
extract showed similar behaviour, except in its activity against C. tropicalis ATCC 750, 
where it demonstrated strong activity (MIC = 0.156 mg/ml). In the case of R. micrantha 
extract, a different profile was found, as it showed a strong effect against the four strains 
assayed. This higher activity of R. micrantha extract could explain its effective and 
traditional use to treat acne and skin conditions caused by organisms closely related with 
Candida species [27]. The fresh leaves extract of C. ladanifer was a strong inhibitor of C. 
albicans ATCC 90028, C. glabrata ATCC 2001 and C. parapsilosis ATCC 22019 growth 
(MIC < 0.05 mg/ml), and a moderate inhibitor of C. tropicalis ATCC 750 growth (MIC = 
0.625 mg/ml). Bruni et al. [28] also demonstrated that C. albicans ATCC 48274 were 
markedly inhibited by oils rich in phenolics, aldehydes and alcohols. In fact, the results of 
chemical characterization performed by Barros et al. [22] showed that the plant extract of 
C. ladanifer was mostly derived from its phenolic compounds. This feature could be an 
explanation for the strong antifungal activity caused by C. ladanifer extract against the 
Candida species under study. 
Additionally, the effect of the extracts on Candida species viability was assessed by 
measuring the number of colony forming units (CFUs). CFU enumeration (Figure 2.1) 
showed that antifungal activity was dependent on the test species. This evaluation is 
essential to differentiate fungicidal and fungistatic activity. The results showed that all the 
extracts yielded strong activity against the four Candida species studied (P<0.001).  
It should be noted that all the extracts caused at least a 2 Log reduction in CFUs 
for all strains, when tested at the lowest concentration (0.05 mg/ml). Candida glabrata 
ATCC 2001 was the strain that appeared to be most susceptible of those tested, with > 3 
Log reduction in CFUs (Figure 2.1 b).  
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Figure 2.1 – Logarithm of number cells of C. albicans ATCC 90028 (a), C. glabrata ATCC 2001 (b), C. 
parapsilosis ATCC 22019 (c) and C. tropicalis ATCC 750 (d) cultured in different concentrations of four plant 
extracts, formed in SDB after 48 h. Error bars represent standard deviation. Concentrations that are 
significantly different (*** P<0.001) of each compound compared to control.
 
At concentrations of 1.25 mg/ml and 0.625 mg/ml respectively, only R. micrantha and C. 
ladanifer extracts were able to completely eliminate all C. glabrata ATCC 2001 cells (Figure 
2.1 b). These results confirm the fungicidal effect of these plant extracts against C. 
glabrata ATCC 2001, compared with the fungistatic effect of the other two extracts. F. 
ulmaria and R. micrantha extracts caused similar effects against C. parapsilosis. However, 
C. sativa extract was not total inhibitory of C. parapsilosis, even when tested at its highest 
concentrations, and R. micrantha extract only produced total CFUs reduction at 
concentrations >2.5 mg/ml (Figure 2.1 c). C. tropicalis ATCC 22019 was highly 
susceptibility to C. sativa, F. ulmaria and R. micrantha (flower extracts), and importantly at 
concentrations >1.25 mg/ml, all these assayed extracts were able to cause total inhibition 
of the growth of this fungal strain (Figure 2.1 d). It is known that C. tropicalis is often 
Chapter II 
40  
associated with urinary tract infections [29] and extracts of F. ulmaria are traditionally 
used to treat these infections [30]. Interestingly, despite C. tropicalis being tested species 
with highest genetic similarity to C. albicans [31], relative sensitivities of these species to 
all assayed extracts varied markedly. C. albicans was deemed to be most tolerant to these 
tested agents with none of the flower extracts able to give total inhibition of this species. 
However, the fresh leaves extract of C. ladanifer was able to completely reduce C. albicans 
growth at its highest concentration (5 mg/ml) tested. No studies concerning the antifungal 
activity of phenolic extracts from C. ladanifer are currently evident in the literature. 
However, Barrajón-Catalán et al. [32] reported on the antibacterial activity of a C. ladanifer 
aqueous extract against Gram-positive (Staphylococcus aureus) and Gram-negative 
(Escherichia coli) and deemed it more active against Gram-positive bacteria. 
2.3.2. Antifungal activity of the phenolic compounds 
Phenolic compounds are involved in plant growth and reproduction, and also can 
provide resistance against plant pathogens and even predators, protecting crops and seed 
from diseases [33,34]. Over 9000 natural antimicrobials have been identified, and these 
can exhibit anti-carcinogenic, anti-inflammatory, anti-oxidant [35] along with antibacterial 
and antifungal effects. The compounds isolated from each extract are presented in Table 
2.2. 
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Table 2.2 – Presence or absence of each phenolic compound in the studied extracts (F. ulmaria, C. sativa, 
R. micrantha, C. multiflorus and C. ladanifer) 
 
Natural 
Compound 
Plant extract 
Filipendula 
ulmaria [21] 
Castanea 
sativa [21] 
Rosa 
micrantha [21] 
Cytisus 
multiflorus [23] 
Cistus 
ladanifer [22] 
Caffeic acid + - - - - 
Ellagic acid - - - - + 
Gallic acid + + - - - 
Apigenin - - - + + 
Catechin - + + - - 
Kaempferol - + + + + 
Luteolin - - - + - 
Quercetin + + + + + 
(+), presence; (-), absence of respective natural compound 
 
In order to select the most likely antifungal compounds to be further examined, a 
disc diffusion method was performed according to the guidelines in NCCLS, M27-A2 
document [24], with some modifications using the least and the most affected Candida 
species by the extracts (C. albicans ATCC 90028 and C. glabrata ATCC 2001, 
respectively) and are presented in Table 2.3. 
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Table 2.3 – Efficacy of phenolic compounds (1 mg/ml) identified in wild plants from North Eastern Portugal 
Candida species
 
 C. albicans 
ATCC 90028 
C. glabrata 
ATCC 2001 
Caffeic acid + - 
Ellagic acid - - 
Gallic acid + + 
Apigenin - + 
Catechin + + 
Kaempferol - + 
Luteolin - - 
Quercetin - - 
                                        (-), absence of halo; (+), presence of halo (≈3-6mm) 
The results presented in Table 2.3, clearly demonstrate that gallic acid and 
catechin possessed antifungal activity against the Candida species tested. Hong et al. [36] 
confirmed that gallic acid a bioactive compound capable of inhibiting and killing C. 
albicans cells. Three phenolic compounds (ellagic acid, luteolin and quercetin) were not 
found to exhibit antifungal activity. From the evaluated compounds, gallic acid (phenolic 
acid), catechin (flavan-3-ols), luteolin (flavone) and quercetin (flavonol) [21–23], were 
chosen, for subsequent assays, due to their chemical characteristics and by the presence 
and absence of antifungal activity in the halo test. The MIC values of these four phenolic 
compounds were determined and ranged from 0.156 to 1.250 mg/ml (Table 2.4). 
Additionally, the MIC values were also confirmed determining Candida planktonic cells 
viability, by CFUs determination (Figure 2.2).  
 
 
 
New natural antifungal strategy
 
 
43  
 
Table 2.4 – Minimum inhibitory concentration (MIC; mg/ml) values obtained with gallic acid, catechin, 
luteolin and quercetin against Candida species 
 
Compounds 
MIC (mg/ml) 
C. albicans 
ATCC 90028 
C. glabrata 
ATCC 2001 
C. parapsilosis 
ATCC 22019 
C. tropicalis 
ATCC 750 
Gallic acid < 0.156 < 0.156 < 0.156 < 0.156 
Catechin < 0.156 0.625 0.625 1.250 
Luteolin 0.625 0.625 0.625 1.250 
Quercetin 0.625 1.250 1.250 1.250 
 
The results presented in Table 2.4 clearly demonstrated, as expected from the 
previous evaluation (Table 2.3), that gallic acid had highest (MIC < 0.156 mg/ml) 
antifungal activity against planktonic Candida cells. Even though, the actual mechanism of 
action of gallic acid on yeast cells has not been widely studied. Hong et al. [36] proved 
that gallic acid present in hydrolysable tannin extracted from barks of Rhizophora apiculata 
possessed anti-C. albicans activity.  Additionally, catechin presented a similar effect 
against C. albicans ATCC 90028. It is important to highlight that the catechin, exhibited 
higher activity than reported by Haghighi et al. [37], who found an MIC value of 9.47 
mg/ml against C. albicans. Although, luteolin has been previously reported to exhibit 
antimicrobial activity against Bacillus cereus and Salmonella enteritidis [38] and quercetin 
against Staphylococcus aureus, Escherichia coli and Pseudomonas fluorescens [39], in 
this present study, these phenolic compounds demonstrated a lower activity against all 
Candida species (≥ 0.625 mg/ml). The high resistance (MIC=1.250 mg/ml) of C. 
tropicalis ATCC 750 to all the tested flavonoids, with exception of gallic acid, should be 
noted.   
In accordance with MICs values that we have obtained for traditional antifungal agents (C. 
glabrata ATCC 2001 0.625-1.250 mg/ml of fluconazole [40]) we consider the MICs values 
acceptable to explore as potential future candidates in the treatment of candidosis.  
Furthermore, many studies have focused on natural compounds and plant-derived active 
principles as possible alternative treatments against Candida infections [41–43]. 
Chapter II 
44  
Measuring Candida viability (CFUs determination) (Figure 2.2) is important when 
distinguishing between fungicidal and fungistatic effects.  
 
Figure 2.2 – Logarithmic number of C. albicans ATCC 90028 (a), C. glabrata ATCC 2001 (b), C. parapsilosis 
ATCC 22019 (c) and C. tropicalis ATCC 750 (d) grown in presence of increased concentrations of gallic acid, 
catechin, luteolin and quercetin, after 48 h. Error bars represent standard deviation. Concentrations that are 
significantly different (*P<0.05, **P<0.01, *** P<0.001) of each compound compared to control. 
 
The cell culture results confirmed that gallic acid had the highest antifungal activity 
(P<0.01 at all concentrations) against Candida planktonic cells (Figure 2.2 a-d). It should 
be noted that, gallic acid resulted in at least a 2 Log reduction in the CFUs of all tested 
species, at its lowest concentration (0.156 mg/ml). Interestingly, this phenolic acid also 
totally killed C. parapsilosis ATCC 22019 (Figure 2.2 c) and C. tropicalis ATCC 750 (Figure 
2.2 d) planktonic cells at concentrations > 0.625 mg/ml (P<0.001) and 1.25 mg/ml 
(P<0.001), respectively. Despite, the fact that the mechanism of action of gallic acid on 
yeast cells has not been established, it can be proposed that it acts by disrupting the 
structure of the cell membrane and inhibiting the normal budding process [44–46]. 
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Candida glabrata ATCC 2001 was the species that generally presented the highest initial 
reduction for all phenolic compounds tested with more than 2 Log reduction in CFUs at 
0.156 mg/ml, (P<0.001) (Figure 2.2 b). However, in contrast to C. tropicalis ATCC 750 
and C. parapsilosis ATCC 22019, gallic acid was unable to completely eradicate C. 
glabrata ATCC 2001 at any of the tested concentrations. Furthermore, this fungistatic 
effect was also observed against C. albicans ATCC 90028 (Figure 2.2 a). Catechin and 
luteolin had similar effects against C. parapsilosis ATCC 22019, causing > 3 Log CFU 
reduction at 1.25 mg/ml, (P<0.001), (Figure 2.2 c). In this study, C. tropicalis ATCC 750 
was the species that showed the lowest susceptibility for all flavonoids, with less than 1 
Log CFU reduction, even for the highest concentration tested (Figure 2.2 d).  
Regarding all the results it was interesting to note that although gallic acid 
presented the highest antifungal activity, it was not present in R. micrantha, which was the 
plant extract that showed highest inhibition. Therefore, it should be highlighted that 
phenolic compounds have a synergistic effect within the extracts and so there was no 
direct relation in their activities. 
2.3.3. Antifungal activity against biofilms of the phenolic compounds 
In most natural environments, microorganisms exist predominantly as biofilms 
rather than as planktonic or free-floating cells [47]. So, the second aim of this work was to 
test the activity of the phenolic compounds against Candida species pre-formed biofilms. 
For that, the relative number of viable cells within the biofilm was evaluated by 
enumerating CFUs (Figure 2.3). Antimicrobial resistance by biofilms is a phenomenon 
consistently evident across model microbial systems [3,48] and is of great clinical 
relevance [49]. Hawser et al. [50], firstly demonstrated the resistance effect of Candida 
biofilms to traditional antifungal agents. As such, any evidence of activity against biofilm-
associated organisms would represent an important new finding.  
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Figure 2.3 – Logarithmic number of C. albicans ATCC 90028 (a), C. glabrata ATCC 2001 (b), C. parapsilosis 
ATCC 22019 (c) and C. tropicalis ATCC 750 (d) cells in the biofilm treated with increasing concentrations of 
gallic acid, catechin, luteolin and quercetin, after 24 h biofilm formation in RPMI 1640. Error bars represent 
standard deviation. Concentrations that are significantly different (*P<0.05) of each compound control. 
 
The effect of the phenolic compounds on Candida biofilms (Figure 2.3) revealed a 
decrease of susceptibility of these microorganisms comparatively to planktonic 
counterparts (Figure 2.2). Gallic acid, the phenolic compound that presented the highest 
effect for planktonic cells, luteolin and quercetin, were only able to reduce C. glabrata 
ATCC 2001 (Figure 2.3 b), C. parapsilosis ATCC 22019 (Figure 2.3 c) and C. tropicalis 
ATCC 750 (Figure 2.3 d) biofilms CFUs by 2 Log at the highest concentration tested 
(P<0.05).  
In terms of species, C. albicans ATCC 90028 biofilms were the most resistant to 
all compounds, where the most active agents were gallic acid and quercetin (P<0.05) 
(Figure 2.3 a). Catechin were the phenolic compound which demonstrated the lowest 
effect, with only 1 Log CFU reduction at the highest concentration tested with C. 
New natural antifungal strategy
 
 
47  
parapsilosis ATCC 22019 (Figure 2.3 c).  
Biofilms are organised and structured communities embedded within a matrix of 
extracellular material [47]. The structure of the Candida biofilm matrix and its composition 
is known to be highly species dependent [47,51]. For example, C. albicans ATCC 90028 
biofilm structure in polystyrene plates involves, generally, two distinct layers: a thin, basal 
yeast layer and a thicker, less compact hyphal layer and C. parapsilosis ATCC 22019 
biofilms are thinner, less structured, and consist exclusively of aggregated blastospores 
[52], which could be the reason for the different results obtained for each Candida 
species. 
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Abstract 
Candida species are the most common cause of mucosal and invasive fungal 
infections in humans. Vaginal candidosis (VC) is an infection of the vaginal epithelium 
caused primarily by Candida albicans. However, Candida glabrata has also emerged as an 
important pathogen in human infection. Relatively little is known about the role of C. 
albicans and C. glabrata during co-infection of vaginal epithelium, which is important, 
given potential synergistic effects and relative difference in antifungal susceptibilities. The 
aim of this study was therefore to investigate the in vitro co-infection of a reconstituted 
vaginal epithelium (RHVE) by C. albicans and C. glabrata.  
The ability of both species to invade and colonise the (RHVE) was examined using 
species-specific peptide nucleic acid (PNA) probe hybridisation, confocal laser scanning 
microscopy (CLSM) and a novel qRT-PCR protocol for Candida quantification in the tissues. 
RHVE damage was evaluated by measuring lactate dehydrogenase (LDH) activity. Candida 
virulence gene expression (HWP1, ALS, EPA, PLB, PLD and SAP) was evaluated by 
quantitative RT-PCR. The results confirmed the effectiveness of RHVE as an in vitro model 
to study Candida virulence attributes and showed that whilst both species induced damage 
to the RHVE, this was notably less with C. glabrata. Interestingly, there was a significant 
increase in C. glabrata RHVE colonisation and invasiveness when it was added to the 
tissue with C. albicans. The extent of RHVE damage caused by the two species appeared 
to be primarily dependent on the process of invasion. Of the virulence genes assayed, 
HWP1, PLD1 and ALS3 were deemed to be most associated with pathogenicity in the 
model. 
In conclusion, for the first time, we have demonstrated that the RHVE model 
coupled with specific tools of analysis, allows assessment of Candida colonisation and 
invasion in single and co-infection. Using this model we have demonstrated that C. 
albicans enhanced C. glabrata colonisation, invasion and tissue damages, which was also 
evidenced by the expression of virulence genes. 
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3.1. Introduction 
Several Candida species can colonise human mucosal surfaces as harmless 
commensals. Normally, infection (candidosis) does not occur due to the host’s effective 
innate and adaptive immune responses. However, debilitation of the host often results in 
candidosis, which most frequently manifests as superficial infections of moist mucosal 
surfaces, such as those of the vagina and oral cavity [1,2]. Amongst the many causes of 
vaginitis, vaginal candidosis (VC) is the second most common after bacterial vaginosis.  VC 
is diagnosed in up to 40% of women with vaginal complaints in the primary care setting 
[3]. Approximately 75% of women experience at least one episode of VC during their lives 
[4,5].  
Candida albicans is regarded as the most frequent species involved in both 
colonisation and infection [2,6]. However, there has been a notable increase in the relative 
proportion of infections caused by non-Candida albicans Candida (NCAC) species [6]. An 
important species in this regard is Candida glabrata, which is now the second leading 
cause of both blood stream and mucosal candidosis in the United State of America [6,7]. 
C. glabrata is also the primary NCAC species emerging in VC, accounting for up to 14% of 
infections in immune-competent women [8,9]. 
Several model systems have been used to study Candida-host interactions, 
including murine models [10]. Murine models of oral candidosis have identified several 
potential virulence factors that may play a role in pathogenesis [11,12]. However, since C. 
albicans does not naturally colonise mice, murine models do not necessarily adequately 
reflect human candidosis [13], which makes results difficult to interpret.  
The human epithelium is a complex multi-layered, multi-cellular tissue consisting 
of increasingly differentiated epithelial cells [14,15] and in recent years, multi-layered 
organotypic three-dimensional in vitro culture systems have been developed to mimic 
human epithelium [16,17]. Reconstituted human vaginal epithelium (RHVE), is a biological 
product commercialised by SkinEthic Laboratories (Nice, France) and is based upon the 
A431 vaginal squamous cell carcinoma cell line. The epithelium has successfully been 
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used to study in vitro mechanisms of tissue degradation and virulence gene expression 
following infection with Candida species [18].  
Putative Candida virulence factors include the ability to exhibit morphological 
transition, adhere to host tissues and develop as biofilms, and secrete hydrolytic enzymes. 
In the case of the latter, secreted aspartyl proteinases (SAPs) are considered highly 
important enzymes in candidosis, which are able to degrade many human proteins at 
lesional sites, facilitating invasion of Candida into the epithelium [19]. Other tissue 
degrading enzymes produced by Candida include phospholipases, which hydrolyse one or 
more ester linkages of glycerophospholipids [20]. Host cell recognition and colonisation by 
Candida is also facilitated by adhesins, such as Agglutinin-Like Sequence (ALS) proteins 
and Hyphal Wall Protein (HWP) [21].  
The aim of this study was to characterise C. glabrata and C. albicans co-infection 
of human epithelium by using an RHVE model, coupled with confocal laser scanning 
microscopy (CLSM) and quantitative real-time polymerase chain reaction (qRT-PCR). 
Analysis of HWP, ALS, phospholipase B and D (PLB and PLD), SAP and epithelial adhesion 
(EPA) virulence gene expression was also undertaken. 
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3.2. Materials and methods 
3.2.1. Microorganisms 
Three clinical isolates of Candida were used in this study and isolated from the 
oral cavity (C. albicans 324LA/94 and C. glabrata D1) and vagina (C. glabrata 585626). 
The oral isolate of C. albicans was obtained from the culture collection of the School of 
Dentistry, Cardiff, UK and the oral strain of C. glabrata was acquired from the biofilm 
group of the Centre of Biological Engineering, Minho University (Braga, Portugal). The 
strain isolated from vaginal infection was gifted from the culture collection of the Hospital 
de Braga (Portugal). In addition to these clinical isolates, two reference strains, namely, C. 
albicans ATCC 90028 and C. glabrata ATCC 2001 (obtained from the American Type 
Culture Collection) were also included in this study. The Candida strains were selected 
based on their previously determined ability to invade a reconstituted human oral 
epithelium [22]. The identity of all strains was confirmed by PCR-based sequencing using 
specific primers ITS1 (5´-TCCGTAGGTGAACCTGCGG-3´) and ITS4 (5´-
TCCTCCGCTTATTGATATGC-3´)[23]. 
3.2.2. Culture of Candida 
For each experiment, isolates were cultured on Sabouraud’s Dextrose Agar (SDA) 
(Merck, Darmstadt, Germany) for 24 h at 37°C. The isolates were then sub-cultured 
overnight in Yeast Nitrogen Base medium (YNB; BD Diagnostics, Cowley, UK) 
supplemented with 0.5% glucose (w/v) at 37°C under agitation at 120 rev/min. After 
incubation, cells were harvested by centrifugation at 3000 g for 10 min at 4°C and 
washed twice in 10 ml of Phosphate Buffered Saline (PBS; pH 7, 0.1 M). The cellular 
density of each strain was adjusted to 2x106 cells/ml in SkinEthic maintenance medium 
(SkinEthic Laboratories, Lyon, France) using an improved Neubauer haemocytometer 
(Marienfild, Land-Könicshofen, Germany).  
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3.2.3. Infection of a reconstituted human vaginal epithelium  
To study in vitro single and co-infection of vaginal epithelium by C. albicans and C. 
glabrata, a commercially available reconstituted human vaginal epithelium (RHVE) 
(SkinEthic Laboratories; Nice, France) was used as an in vitro model of vaginal candidosis. 
RHVE tissue inserts (0.5 cm2) were placed in 12-well tissue culture plates. As a negative 
control, 1 ml of maintenance medium was added to a RHVE tissue preparation. To study 
single species infection, 5 RHVE tissues were inoculated with 1 ml of standardised 
suspensions of each Candida isolate prepared as previously described.  
In dual species studies, C. albicans ATCC 90028 (500 µl; 2×106 cells/ml) or C. 
albicans 324LA/94 was combined with one of C. glabrata D1, ATCC 2001, or 585626 
(500 µl; 2×106 cells/ml). Each dual species experiment was repeated in 3 independent 
experiments.  
All infected tissues were incubated at 37°C in a 5% CO2 environment in saturated 
humidity for 24 h. After incubation, the tissue was rinsed twice in 1 ml of PBS to remove 
non-adherent Candida cells, and the tissue was then bisected, with one half being used for 
CLSM analysis and the other for qRT-PCR. 
3.2.4. Histological techniques 
The RHVE tissue for CLSM analysis was fixed in 2% (v/v) formalin and stored at 
4°C until histological processing. Tissues were then dehydrated, cleared, and infiltrated 
with paraffin wax embedding material. The formalin-fixed, paraffin-embedded (FFPE) 
tissues were stored at room temperature. The tissues were cut (20 µm sections) and 
placed on Histobond+ coated microscope slides (Raymond A Lamb, East Sussex, UK), de-
waxed, and processed through xylene, ethanol, and water before peptide nucleic acid 
probe hybridization. 
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3.2.5. Peptide nucleic acid fluorescent in situ hybridization 
Peptide nucleic acid probe fluorescence in situ hybridisation (PNA FISH) was 
employed on tissue sections using the Light PNA FISHTM kit (AdvanDx Inc., Woburn MA, 
USA). These species-specific probes were utilised to study the invasion of the RHVE by C. 
albicans and C. glabrata. The Light PNA FISHTM kit had previously been developed and 
evaluated using multicolour labelled fluorescent PNA probes targeting specific 26S rRNA 
sequences of C. albicans and C. glabrata. The assay was performed in accordance with 
the guidelines of the manufacturer. Tissue sections on microscope slides were overlaid 
with 1 drop of the respective PNA probes.  After 90 min of incubation, in the dark in a 
humidified chamber at 55°C, unbound probe was removed by washing the slides using a 
previously warmed wash solution at 55°C for 30 min. The preparation was then mounted 
with a medium suitable for fluorescence microscopy, which also contained 4',6-diamidino-
2-phenylindole (DAPI) for detection of epithelial cell nuclei (Vectashield, Vector laboratories, 
California, USA). Samples were examined by CLSM, where C. albicans and C. glabrata 
were represented by bright green and red fluorescence, respectively. 
3.2.6. Confocal laser scanning microscopy (CLSM) 
Tissue sections (20 µm) hybridised with PNA probes were observed by CLSM, 
using a Leica TCS SP2 AOBS spectral confocal microscope (Leica Microsystems GmbH, 
Wetzlar, Germany) to analyse the level of colonisation and morphological characteristics of 
C. albicans and C. glabrata in single and co-infection of the surface of RHVE tissues. 
Sections were scanned through the full depth using appropriate settings for single, double 
or triple channel fluorescence recordings. Fluorescein-labelled PNA was used for detection 
of C. albicans (laser excitation line 492nm and emissions detected 520nm); Tamara-labelled 
PNA was used for detection of C. glabrata (laser excitation line 565nm and emissions 
detected 580nm) and DAPI (laser excitation line 485nm and emissions detected 410-485nm) 
for nuclear context of keratinocytes. For multi-channel recordings, fluorochromes were 
scanned sequentially to eliminate spectral overlap between probes. Selected images were 
presented either as single confocal optical sections or maximum intensity type 
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constructions. A specific classification scale was used to express the level of Candida 
RHVE colonisation. Colonisation categories were as follows: extensive (fungal elements 
totally covered the surface); moderate (fungal elements covered a large proportion of 
surface) and sparse (fungal elements covered only limited areas of surface). Similarly, the 
following categories defined the level of Candida RHVE invasion: high (fungal elements 
totally invaded all RHVE keratinocytes layers); moderate (fungal elements moderately 
invaded the first RHVE top keratinocytes layers) and low (fungal elements only formed 
isolated clusters in the first RHVE keratinocytes layer). 
3.2.7. Lactase dehydrogenase (LDH) activity 
The extracellular activity of LDH released from RHVE cells was monitored as an 
indicator of tissue cell damage. LDH released in the maintenance medium of the control 
RHVE, devoid of Candida, as well as infected RVHE was measured at 24 h using the 
CytoTox-ONETM Homogeneous Membrane Integrity Assay kit (Promega, Madison, WI, USA). 
LDH activity from Candida cells in a planktonic control (prepared as described for the 
infection model but devoid of RHVE) was subtracted from the LDH activity of the tissues 
infected with the different single and co-infection Candida species. The LDH released 
during single or co-infection with the different C. albicans and C. glabrata strains was then 
expressed as relative LDH activity to the untreated control tissue. LDH activity was 
analysed spectrophotometrically (FLUOstar OPTIMA, BMG Labtech, Ortenberg/Germany) 
by measuring the NADH disappearance rate at 544nm excitation and 590nm emission during 
the LDH-catalysed conversion of pyruvate to lactate. All experiments were performed in 
triplicate.  
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3.2.8. Quantification of Candida species in RHVE tissue sections 
I- DNA extraction  
After histological processing, four tissue sections of 20 µm were cut from each 12 
FFPE tissues and placed in a sterile 1.5 ml microcentrifuge tubes (Eppendorf AG, 
Hamburg, Germany). Paraffin was removed using 1 ml of xylene and the tubes vigorously 
vortexed for 10 seconds. After centrifugation (13,000 g for 2 min), the supernatant was 
discarded and the residual xylene removed from the tissue pellet by adding 1 ml of 
absolute ethanol. After repeat centrifugation, the supernatant was carefully removed. The 
tubes were left open for 10 min at room temperature and DNA for PCR analysis was 
extracted from the tissue pellet using a commercial DNA extraction kit (QIAamp® DNA 
FFPE Tissue, Qiagen). 
II- Quantification of DNA by Real-time PCR 
Candida were quantified using real-time PCR in an ABI Prism 7000 (Applied 
Biosystems, USA). For each sample, 5 µl of extracted DNA was added to a PCR solution 
containing 12.5 µl of 2× qPCR Master Mix and 0.25 µl of reference dye (SYBR® Green 
JumpStart™ Taq ReadyMix™, Sigma-Aldrich, St Louis, USA), 2 µl of 3 µM of each primer 
(Sigma-Aldrich, St Louis, USA)  (Table 3.1) and 3.25 µl of dH2O (Promega, Madison, WI, 
USA). Negative controls were performed using a reaction mixture with dH2O (Promega, 
Madison, WI, USA) substituting for the template DNA. Template DNA for each positive 
control was obtained from FFPE tissues after the step of DNA extraction described above.  
PCR cycling conditions consisted of an initial denaturation step at 94°C for 2 min, followed 
by 40 cycles of denaturation at 94°C for 15 s primer annealing at 60°C for 30 s and 
extension at 72°C for 30 s. In each cycle, a dissociation stage at 60°C was run to 
generate a melting curve for verification of amplification product specificity.  
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Table 3.1 – Primers used for Real-time PCR screening for C. albicans and C. glabrata 
 
Sequence (5’→ 3’) Primer Target 
 
GAGCGTCGTTTCTCCCTCAAACCGCTGG Forward C. albicans 
strains GGTGGACGTTACCGCCGCAAGCAATGTT Reverse 
 
ATTTGCATGCGCTTGCCCACGAATCC Forward C. glabrata 
strains ACGTCTGATCCAATCAATGGCTGGTGA Reverse 
Calibration curves (Ct vs. Log cells) for each Candida isolate were constructed 
using the same PCR protocol as described above (data not shown). For these, serial 
dilutions of the Candida were prepared and the DNA for PCR analysis extracted from the 
planktonic cell pellet using the DNA extraction kit (QIAamp® DNA FFPE Tissue, Qiagen, 
Crawley, UK) with some modifications. 
3.2.9. Analysis of candidal virulence gene expression 
I- RNA extraction  
For gene expression analysis, each Candida was cultured as previously described. 
For RNA extraction, fresh RHVE tissue removed with a scalpel directly from the plastic 
scaffold was placed in a 1.5 ml microcentrifuge tube (QIAshredder®, Qiagen, Crawley, 
UK) with 600 µl of RLT buffer containing 500 µl of glass beads (0.5 mm diameter) and 
1/100 (v/v) of ß-mercaptoethanol. This final mix was homogenised twice for 30 s using a 
Mini-Bead- Beater-8 (Stratech Scientific, Soham, UK) to lyse cells. The RNeasy Mini Kit 
(Qiagen, Crawley, UK) was then used to complete total RNA extraction from the tissue 
according to the manufacturer’s recommended protocol. To remove any DNA 
contamination, samples were treated with RNase-Free DNase I (Invitrogen, Carlsbad, 
USA). The RNA extraction was performed on three different independents assays. 
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II- Synthesis of cDNA 
From each sample, 0.5 µg of RNA was used for complementary DNA (cDNA) 
synthesis. RNA (14 µl) was incubated with 1 µl (50 µg/ml) of random primer mix 
(Promega, USA) in RNase free dH2O at 70°C for 5 min. To this solution, 10 µl of a master 
mix containing 5 µl of M-MLV Reaction buffer (5×), 1 µl of each deoxynucleoside 
triphosphate (dNTP, 10 µM), 1 µl of RNasin Plus RNase inhibitor, 1 µl of M-MLV enzyme 
and 2 µl RNase free dH2O was added. All reagents used in these experiments were from 
Promega Corporation, UK. Synthesis of cDNA was performed at 37°C for 1 h. 
III- Primer design 
Primers for ‘housekeeping genes’ (ACT1_alb and ACT1_gla), and putative 
virulence genes (ALS, HWP, EPA, PLB, PLD and SAP) were designed using Primer3 web 
software (http://fokker.wi.mit.edu). Full-length gene sequences were obtained from the C. 
albicans and C. glabrata database http://www.candidagenome.org [24]. The specificity of 
each primer was confirmed by comparing its respective sequences to the C. albicans and 
C. glabrata database using BLAST [25]. To verify the specificity of each primer pair for its 
corresponding target gene, PCR using the various primer pairs was applied to genomic 
DNA extracted from each of the Candida strains. 
The sequences of the primers developed in the present study are provided in 
Table 3.2 and 3.3. 
 
Table 3.2 – Forward (FW) and reverse (RV) housekeeping primers used for Real-time PCR 
 
 Sequence (5’→ 3’) Orientation Target 
Housekeeping gene 
(C. albicans) 
TGCTGAACGTATGCAAAAGG FW 
ACT1_alb 
TGAACAATGGATGGACCAGA RV 
Housekeeping gene 
(C. glabrata) 
TTGCCACACGCTATTTTGAG FW 
ACT1_gla 
ACCATCTGGCAATTCGTAGG RV 
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Table 3.3 – Forward (FW) and reverse (RV) primers used for Real-time PCR 
 
 Sequence (5’→ 3’) Orientation Target 
HWP gene 
TCTACTGCTCCAGCCACTGA FW 
HWP1 
CCAGCAGGAATTGTTTCCAT RV 
AL
S 
ge
ne
s 
CCCAACTTGGAATGCTGTTT FW 
ALS1 
TTTCAAAGCGTCGTTCACAG RV 
GCACTTCATTGACTGGAGCA FW 
ALS2 
TCATTGTTGCCACCTTGTGT RV 
CTGGACCACCAGGAAACACT FW 
ALS3 
GGTGGAGCGGTGACAGTAGT RV 
TCCACAGTTTCTCGTCCACA FW 
ALS4 
ATTGCCACGCTTGTTTTACC RV 
GTTCAGACATGCCATCATCG FW 
ALS5 
CCAAGTGATCAGGGTGGACT RV 
ATCGGAAGCTCCAAATTCCT FW 
ALS6 
AGGATGTTTAGTGGCGGATG RV 
GACCTTTTGTGGATGCGATT FW 
ALS7 
TTTTCTGGAGTCGGGAAATG RV 
GTGCCACAATGTGAGAATGG FW 
ALS9 
GTGCCACAATGTGAGAATGG RV 
EP
A 
ge
ne
s 
ATGTGGCTCTGGGTTTTACG FW 
EPA1 
TGGTCCGTATGGGCTAGGTA RV 
TTATGCCGTATGGGGTTCTC FW 
EPA6  
GAGTCAACTGAGGCACACGA RV 
AGGATGCACACCCGAAATAG FW 
EPA7 
TTACCAGCCCCAAAATTCAC RV 
Ph
os
ph
ol
ip
as
e 
B
 
ge
ne
s 
 
GCTCTTTTCAACGAAGCGGTGT FW 
PLB1 
GCCATCTTCTCCACCGTCAACT RV 
CAATACTAGCCGCGTTGGGAAG FW 
PLB2 
GCCCATGAAAAACCCTGCATTA RV 
TCCCAATTGTTGTTGCTGATGG FW 
PLB3 
CCGCATTATCAAACCCACCAAT RV 
TCGTCCGGGTCTTCAAGTTCTC FW 
PLB5 
ATCTCCCGAATCCCCGTCTAAA RV 
Phospholipase D gene 
GCCAAGAGAGCAAGGGTTAGCA FW 
PLD1 
CGGATTCGTCATCCATTTCTCC RV 
Se
cr
et
ed
 A
sp
ar
ty
l P
ro
te
as
e 
ge
ne
s 
CAATGCTGCCACTGGACAAATC FW 
SAP1 
CAATTCAGCTTGGAAGGCATCA RV 
ACCGTTGGATTTGGTGGTGTTT FW 
SAP2 
ATTATTTGTCCCGTGGCAGCAT RV 
TGGTCCCCAAGGTGAAATCAAT FW 
SAP3  
TGGATCTTGTCCTTGACCAGCTT RV 
GTCAATGTCAACGCTGGTGTCC FW 
SAP4 
ATTCCGAAGCAGGAACGGAAAT RV 
ATCTTCCCGCACTTCCCAAAAT FW 
SAP5 
TCGCCGCTTTGAAAACCAATAC RV 
AAAATGGCGTGGTGACAGAGGT FW 
SAP6 
CGTTGGCTTGGAAACCAATACC RV 
ACGGGTGTTGTTTTGGATACCG FW 
SAP9 
GTCGACTGTTCTGCTGGAGTCG RV 
CCCGTTGATTCCAAAAGTCAGC FW 
SAP10 
TCGCCTATCGAAAACCCAAAGA RV 
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IV- Quantitative Real-time PCR 
Real-time PCR was performed in 96-well plates (BrightWhite real-time PCR, Primer 
Design, UK) using the ABI PRISM 7000 (Applied Biosystems, USA). A total of 5 µl of 1:2 
diluted cDNA samples and 20 µl of PCR solution (described above) were added to the 
plates with the respective virulence gene primers. Negative controls (dH2O), as well as, 
non- reverse transcriptase controls (NRT) were included in each run.  Real-time PCR was 
performed with an initial denaturation step at 94°C for 2 min, followed by 40 cycles of 
denaturation at 94°C for 15 s, primer annealing at 54°C for 30 s and extension at 72°C 
for 30 s. In each cycle, a dissociation stage at 60°C was run to generate a melting curve 
for verification of amplification product specificity. Control samples were included on each 
plate to ensure that multiple plates could be compared. The ACT1 gene of C. albicans and 
C. glabrata had previously been used as a reference candidal housekeeping gene and 
were also used in this study. 
All samples were run in triplicate. The Ct value of each sample was determined, 
and the relative gene expression levels calculated using the ΔCt method, which was 
normalized to the housekeeping genes described above.  
3.2.10. Statistical analysis 
Results were compared using one-way analysis of variance (ANOVA) by applying 
Tukey multiple-comparisons test, using Graphpad Prism program for Windows, version 6. 
All tests were performed with a confidence level of 95%. 
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3.3. Results 
3.3.1. In vitro single and co-infection of RHVE 
The surface colonisation and invasion of fresh RHVE by Candida was examined 
after 24 h incubation with C. albicans and C. glabrata strains in single and co-infection 
status (Figures 3.1, 3.2 and Table 3.4). The results showed that all strains were able to 
colonise the RHVE surface in single and co-infection. However, the level of colonisation 
was species, strain and combination dependent.  
 
 
Figure 3.1 – C. albicans and C. glabrata single infection of RHVE after 24 h, assessed by CLSM and YTL 
PNA FISHTM. (A) C. albicans ATCC 90028, (B) C. albicans 324LA/94 (C) C. glabrata ATCC 2001, (D) C. 
glabrata D1 and (E) C. glabrata 585626.
 
Candida albicans ATCC 90028 and C. albicans 324LA/94 (oral strain) exhibited 
the highest level of colonisation (extensive colonisation) of the vaginal epithelial surface in 
single and co-infection (Figures 3.1 A and Figure 3.2 A-C, Figures 3.1 B and Figure 3.2 D-
F, respectively).  
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Figure 3.2 – C. albicans and C. glabrata strains co-infection of RHVE after 24 h, assessed by CLSM and YTL 
PNA FISHTM. (A) C. albicans ATCC 90028 and C. glabrata ATCC 2001, (B) C. albicans ATCC 90028 and C. 
glabrata D1, (C)  C. albicans ATCC 90028 and C. glabrata 585626, (D) C. albicans 324LA/94 and C. 
glabrata ATCC 2001, (E) C. albicans 324LA/94 and C. glabrata D1 and (F) C. albicans 324LA/94 and C. 
glabrata 585626.
 
Although all C. glabrata strains colonised the tissue in single infection, this was 
only sparse when compared with C. albicans.  In general, after 24 h of single infection, 
only limited clusters of C. glabrata were detected on the surface of the keratinocyte layers 
(Figure 3.1 C, D, E).  Additionally, in the presence of C. albicans, all C. glabrata (Figures 
3.2) strains demonstrated increased RHVE colonisation. The co-infection of C. glabrata 
585626 (vaginal strain) with C. albicans 324LA/94 (Figure 3.2 F) actually resulted in the 
C. glabrata having the same level of colonisation as encountered with C. albicans strains 
(i.e. extensive colonisation).  
Furthermore, when tissue invasion was analysed, similar associations were 
evident. Candida albicans again had a high ability to invade the RHVE model, and it was 
possible to detect hyphal and yeast elements totally penetrating the RHVE layers (Figure 
3.1 A-B). In single species infection involving C. glabrata, yeast invasion of the epithelium 
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was not apparent (Figure 3.1 C-E) and superficial detachment of keratinocyte layers was 
not evident. However, as with RHVE colonisation, when C. glabrata were combined with C. 
albicans, the level of invasion of C. glabrata was increased (moderate invasion in all 
combinations) (Figures 3.2). 
Using real-time PCR, it was possible to quantify the number of Candida present in 
the RHVE sections (Table 3.4). Candida albicans was present in higher numbers (4-fold 
more) in the RHVE sections than C. glabrata, corroborating the CSLM observations. In both 
single and mixed species infections, C. albicans ATCC 90028 (4.76 ± 0.21 Log number of 
cells/ml) was present in significantly (P<0.01) higher numbers than C. albicans 324LA/94 
(4.01 ± 0.24 Log number of cells/ml). No statistical differences were evident between the 
levels of C. glabrata in single species RHVE infection.  
Compared with single species infection, it is important to note that the inoculum 
used for each individual species was halved in the co-infection studies (Table 3.4) and 
statistical comparison between single and co-infection assays was not possible. Despite 
this, it is important to emphasise that the number of C. glabrata cells increased 
considerably in all co-infection assays studied. 
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Table 3.4 – Summary findings of C. glabrata and C. albicans single and co-infection of reconstituted human vaginal epithelium at 24 h 
 
Candida strain Origin 
Single Infection Co-Infection C. albicans ATCC Co-Infection C. albicans 324LA/94 
Colonisation Invasion 
qRT-PCR 
(Log number 
of cells/ml) 
Colonisation Invasion 
qRT-PCR 
(Log number 
of cells/ml) 
Colonisation Invasion 
qRT-PCR 
(Log number 
of cells/ml) 
C. albicans 
ATCC 
C. albicans 
324LA/94 
C. glabrata 
strains 
C. glabrata 
strains 
C. albicans ATCC Reference +++ High 4.76 ± 0.21 - - - - - - 
C. albicans 324LA/94 Oral +++ High 
4.01 ± 0.24 
** 
- - - - - - 
C. glabrata ATCC Reference + Low 0.88 ± 0.41 ++ Moderate 
3.87 ± 0.39 
++ Moderate 
2.46 ± 0.35 
2.05 ± 0.23 1.97 ± 0.39 
C. glabrata D1 Oral + Low 0.89 ± 0.46 ++ Moderate 
3.99 ± 0.39 
++ Moderate 
3.01 ± 0.23 
1.89 ± 0.29 2.03 ± 0.22 
C. glabrata 585626 Vaginal + Low 1.30 ± 0.38 ++ Moderate 
4.66 ± 0.26 
+++ Moderate 
3.38 ± 0.26 
2.62 ± 0.21 2.55 ± 17 
(+) sparse colonisation; (++) moderate colonisation; (+++) extensive colonisation;  
** statistically different to reference strain (P<0.01). 
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3.3.2. LDH activity as an indicator of tissue damage 
In order to determine the extent of RHVE damage induced by Candida, the levels 
of LDH activity were measured after 24 h of single and co-infection (Figure 3.3). In single 
infection, C. albicans caused the highest levels of tissue damage (P<0.001), with C. 
albicans 324LA/94 being significantly more damaging than the other strains (P<0.001). In 
the case of single species infection with C. glabrata, only C. glabrata 585626 (vaginal 
strain) resulted in a significant (P<0.01) increase in LDH activity compared to controls.  
 
**,***Strain/combination statistically different to reference strain (P<0.01; P<0.001);  
 
Figure 3.3 – Relative lactate dehydrogenase (LDH) activity measured in the human vaginal epithelium tissue 
culture supernatant after 24 h incubation with different C. albicans and C. glabrata strains in single infection 
and co-infection (A- C. albicans ATCC 90028; B- C. albicans 324LA/94; C- C. glabrata ATCC 2001; D- C. 
glabrata D1; E- C. glabrata 585626).
 
In co-infection studies (Figure 3.3) it is again important to highlight that half of the 
number of each individual species was present in the starting inoculum. Interestingly, the 
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higher tissue damage previously seen with C. albicans 324LA/94 compared with C. 
albicans ATCC 90028 in single infection was not apparent in co-infection assays. Candida 
albicans ATCC 90028 and 324LA/94 combinations with C. glabrata 585626 resulted in 
significantly higher tissue damage (P<0.01; P<0.001, respectively), compared with other 
co-infection combinations.  In all co-infection assays, the tissue damage demonstrated a 
similar profile with respect to that induced by the respective C. glabrata strains. The LDH 
values corroborated with the degree of tissue damage observed by CLSM (Figure 3.1, 3.2 
and Table 3.4). 
 
3.3.3. Gene expression 
qRT-PCR revealed a wide range of expression of Hyphal Wall Protein (HWP1), 
Agglutinin-Like Sequence (ALS), Phospholipase B and D, Secreted Aspartyl Proteinase 
(SAP) (Table 3.5) and Epithelial Adhesin (EPA) genes (Table 3.6) for RHVE single and co-
infection combinations. The results were expressed as the mean expression, relative to the 
expression of ACT1 during RHVE infection. ACT1 gene expression levels were constant in 
all assays.  
HWP1 expression by C. albicans was up regulated during co-infection with all C. glabrata 
strains (Table 3.5). Expression of ALS genes was generally detected, however ALS9 was 
not encountered in any of the analyses. Compared with single species infection, C. 
albicans ALS1 expression was up-regulated for C. albicans ATCC 90028 in association 
with all C. glabrata strains. ALS3 expression demonstrated similar results but for both C. 
albicans strains. Furthermore, for C. albicans 324LA/94 the other ALS genes were down-
regulated when this strain was combined in infection with C. glabrata. Expression of 
Phospholipase B and D gene families by C. albicans was always detected in the samples 
(Table 3.5). All these genes were up-regulated during co-infection of C. albicans 324LA/94 
and C. glabrata 585626. Expression of PLD1 was also up-regulated when C. albicans 
ATCC 90028 was co-infected with C. glabrata 585626. SAP genes were generally detected 
in all samples. However, SAP3 was not expressed by C. albicans 324LA/94 during 
infection of RHVE. For this gene family, it is important to note that in co-infection, both C. 
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albicans with C. glabrata 585626 (vaginal strain) demonstrated a noticeable up -regulation 
of SAP4-10 genes.  
In contrast, Epithelial Adhesin gene expression by C. glabrata did not appear to correlate 
with the level of RHVE colonization and invasion (Table 3.6). In all mixed species 
combinations, expression of this gene family was shown to be principally down regulated, 
and in some cases absent. 
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Table 3.5 – Relative expression of Hyphal Wall Protein 1 (HWP1), Agglutinin-like Sequence (ALS), 
Phospholipase (B and D) and Secreted Aspartyl Protease (SAP) gene families after 24 h of reconstituted 
human vaginal epithelium single and co-infection by different Candida albicans and Candida glabrata strains 
using quantitative RT-PCR
 
Gene 
Single infection 
Co-infection 
 
C. albicans ATCC 90028 C. albicans 324LA/94 
C. albicans 
ATCC 
90028 
C. albicans 
324LA/94 
C. glabrata 
ATCC 2001 
C. glabrata 
D1 
C. glabrata 
585626 
C. glabrata 
ATCC 2001 
C. glabrata 
D1 
C. glabrata 
585626 
HWP1 42 ± 7 50 ± 13 160 ± 13 220 ± 14 227 ± 27 521 ± 53 678 ± 46 750 ± 41 
ALS1 216 ± 53 53 ± 7 859 ± 59 325 ± 22 426 ± 19 12 ± 5 18 ± 3 23 ± 2 
ALS2 110 ± 11 128 ± 21 93 ± 5 141 ± 8 135 ± 9 67 ± 6 82 ± 10 75 ± 8 
ALS3 345 ± 41 273 ± 29 575 ± 68 588 ± 24 1016 ± 166 308 ± 39 329 ± 16 485 ± 41 
ALS4 224 ± 26 304 ± 33 201 ± 25 242 ± 14 187 ± 27 144 ± 13 187 ± 9 243 ± 8 
ALS5 206 ± 21 208 ± 22 174 ± 8 129 ± 17 107 ± 9 106 ± 10 94 ± 7 65 ± 8 
ALS6 374 ± 31 355 ± 40 484 ± 23 84 ± 5 222 ± 27 38 ± 4 44 ± 4 47 ± 5 
ALS7 13 ± 2 32 ± 3 49 ± 7 80 ± 5 88 ± 3 23 ± 2 21 ± 3 ND 
PLB1 31 ± 8 19 ± 5 38 ± 9 14 ± 3 34 ± 3 23 ± 2 10 ± 1 71 ± 10 
PLB2 135 ± 10 102 ± 8 122 ± 18 99 ± 12 166 ± 18 76 ± 3 36 ± 2 206 ± 21 
PLB3 218 ± 11 119 ± 3 179 ± 11 172 ± 9 238 ± 6 74 ± 3 18 ± 3 162 ± 20 
PLB5 248 ± 6 159 ± 11 236 ± 8 126 ± 8 210 ± 2 94 ± 5 82 ± 3 366 ± 31 
PLD1 278 ± 11 214 ± 4 270 ± 6 211 ± 12 390 ± 21 144 ± 5 94 ± 4 389 ± 30 
SAP1 65 ± 9 21 ± 1 62 ± 8 39 ± 4 59 ± 2 26 ± 3 16 ± 1 33 ± 5 
SAP2 182 ± 25 103 ± 6 196 ± 11 116 ± 6 134 ± 2 83 ± 4 34 ± 1 67 ± 6 
SAP3 112 ± 11 ND 139 ± 15 78 ± 6 72 ± 3 ND ND ND 
SAP4 118 ± 14 343 ± 10 224 ± 18 153 ± 14 266 ± 9 257 ± 10 134 ± 4 567 ± 24 
SAP5 56 ± 6 123 ± 17 224 ± 15 214 ± 12 363 ± 22 187 ± 15 69 ± 7 298 ± 19 
SAP6 63 ± 6 243 ± 10 104 ± 6 68 ± 4 117 ± 2 159 ± 12 115 ± 8 366 ± 25 
SAP9 387 ± 17 329 ± 13 454 ± 24 351 ± 15 524 ± 4 244 ± 10 150 ± 9 555 ± 31 
SAP10 103 ± 10 73 ± 3 114 ± 16 78 ± 6 180 ± 7 65 ± 6 31 ± 2 140 ± 14 
ND, indicates that no gene expression was detected. The numbers represent the relative quantity (as a percentage) of 
PCR amplicon compared with the respective Candida housekeeping gene product (ACT1).  
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Table 3.6 – Relative expression of Epithelial Adhesin (EPA) gene family after 24 h of reconstituted human 
vaginal epithelium single and co-infection by Candida albicans and Candida glabrata using quantitative RT-
PCR
 
 
Single infection 
Co-infection 
C. glabrata ATCC 
2001 
C. glabrata D1 C. glabrata 585626 
C. 
glabrata 
ATCC 
2001 
C. 
glabrata 
D1 
C. 
glabrata 
585626 
C. 
albicans 
ATCC 
90028 
C. 
albicans 
324LA/ 
94 
C. 
albicans 
ATCC 
90028 
C. 
albicans 
324LA/ 
94 
C. albicans 
ATCC 
90028 
C. 
albicans 
324LA/
94 
EPA1 72 ± 5 110 ± 12 124 ± 10 60 ± 5 75 ± 3 70 ± 3 63 ± 5 96 ± 5 47 ± 7 
EPA6 18 ± 1 25 ± 3 28 ± 5 13 ± 1 22 ± 2 ND ND ND 18 ± 3 
EPA7 39 ± 1 49± 6 ND 18 ± 3 41 ± 8 22 ± 3 32 ± 2 ND ND 
ND, indicates that no gene expression was detected. The numbers represent the relative quantity (as a percentage) of 
PCR amplicon compared with the respective Candida housekeeping gene product (ACT1).  
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3.4. Discussion 
The mucosal epithelium is highly important in host defense and immune 
surveillance, as it is the first cell layer that initially encounters environmental microbes with 
pathogenic potential [26]. As a result, the characteristic feature of vaginal candidosis is 
chronic inflammation of the mucosa. In recent years, a number of studies have 
investigated colonisation and invasion of reconstituted human epithelium by Candida 
[18,19,27]. In this present study, the aim was to investigate colonisation and invasion of 
single and co-infection of C. albicans and C. glabrata in an in vitro reconstituted human 
vaginal epithelium (RHVE) model.  
The work presented revealed that in single species infection (Figure 3.1 A, B and 
summarized in Table 3.4), both C. albicans strains tested extensively colonised and highly 
invaded the RHVE. Furthermore, C. albicans induced significant change in the vaginal 
keratinocytes structure, disruption of the superficial epithelium and cleft formation between 
the cells in the upper layers. These features have previously been reported in studies using 
RHOE [22,27–29]. After 24 h of incubation, CLSM revealed that C. glabrata were generally 
unable to invade the RHVE (very low invasion, Table 3.4) with few clusters of cells (Figure 
3.1 C-E) within the first layers of the epithelium (sparse colonisation). These findings were 
in agreement with those of Schaller et al. 2002 [28] and Jayatilake et al. 2006 [30] who 
also classified C. glabrata as being non-invasive of RHOE. The differences between both 
species could be explained by the ability of C. albicans to form hyphae and/or 
pseudohyphae, and the absence of this property by C. glabrata [7,21]. Polymorphism and 
the movement of hyphae are indeed previously recognised factors enhancing RHOE 
colonisation and invasion [27,28,31]. 
Whilst the relative degree of C. albicans and C. glabrata RHVE colonisation and 
invasion was markedly species dependent, when the isolates were grouped according to 
clinical origin, there was no obvious association between origin and ability to colonise or 
invade RHVE. This is in agreement with other work performed with Candida species in an 
oral epithelium model [19].  
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In addition to CLSM observations, a molecular method was applied to enumerate 
the Candida able to colonise and invade RHVE. It was interesting to note that although the 
inoculum used in co-infection studies for each strain was halved compared with the single 
infection, the degree of colonisation and invasion of C. albicans in the presence of C. 
glabrata was not affected. Additionally, and as had previously been noticed using RHOE 
infection [22], colonisation by C. glabrata cells was highest when combined with C. 
albicans. Furthermore, C. glabrata invasion also increased in co-infections studies. Thus, 
the presence of C. albicans would appear to enhance invasiveness of C. glabrata in this 
model system, although the mechanism of this remains unclear. One possible explanation 
is that C. glabrata invasion is enhanced because of the damage induced to the epithelium 
by C. albicans hyphae (Figure 3.2). This would facilitate access of C. glabrata to lower 
epithelial layers. It is also possible that C. glabrata yeast could adhere to C. albicans 
hyphae and be transported to lower tissue layers. Kolenbrander et al., 1993 [32] showed 
the ability of different oral microorganisms to adhere to each other (co-aggregation), which 
is known to be important in the development of dental plaque.  
Adhesion of C. albicans to host cells is a key virulence mechanism and is 
associated with expression of Hyphal Wall Protein (HWP) [33]. It is known that the 
glutamine residues in the N-terminal domain of HWP1 are cross-linked by host 
transglutaminase activity to unidentified host proteins and this results in covalent 
attachment of the yeast to host epithelial cells [34]. In this current research, qRT-PCR 
showed that in co-infection, both C. albicans strains exhibited up-regulation of HWP1 
compared with single infection. Based on the qRT-PCR findings it is tempting to speculate 
that RHVE invasion and colonisation by C. glabrata cells is enhanced by the presence of C. 
albicans hyphae following HWP1 up-regulation.  
Expression of adhesins may also be responsible for the different colonisation 
profile and therefore expression of genes of the Agglutinin-Like Sequence (ALS) and 
Epithelial Adhesins (EPA) family were also evaluated. Most ALS proteins have adhesin 
function [35], and the binding domain for most substrates is located in the N terminal. 
ALS3 is a hypha-specific gene expressed by C. albicans hyphae and pseudohyphae, but 
not yeast [36,37]. The expression pattern of the ALS genes (Table 3.5) in C. albicans 
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RHVE single infection assays were generally similar to that observed in the co-infections, 
with exception of ALS3, which was highly increased. Since ALS3 is C. albicans hyphal 
specific, its up-regulation in co-infection studies, might be reflected by increased hyphal 
production leading to enhanced invasion of C. glabrata yeast.  
In vitro adherence of C. glabrata to epithelial cells is primarily mediated by EPA 
genes, which encode cell wall proteins of a large family of putative adhesins [38]. The EPA 
gene family consists of 17–23 members depending on the strain, and along with EPA1, at 
least two other genes have been shown to encode functional adhesins, EPA6 and EPA7 
[39]. EPA1 encodes a lectin that recognises host N-acetyl lactosamine containing 
glycoconjugates, aiding adhesion of yeast to mammalian surfaces. This gene exhibited 
highest expression in all the single C. glabrata assays presented here (Table 3.5). 
However, in co-infection, the majority of the EPA genes studied were down-regulated or 
absent, suggesting that these adhesins were not associated with increased RHVE 
colonisation or invasion by C. glabrata in the co-infection assays. Therefore, other factors 
might be responsible for this behaviour.  
The degree of tissue damage caused by Candida during infection, was evaluated 
in single and co-infection (Figure 3.3) by LDH activity and results agreed with the CLSM 
observations (Figure 3.1, 3.2). Single species infection revealed that C. albicans generated 
more damage than C. glabrata. This result was expected given the fact that C. albicans is 
deemed more pathogenic [40]. LDH activity after co-infection yielded a profile similar to 
the C. glabrata in single infection, but understandably at higher levels because the 
presence of C. albicans. Furthermore, the previously observed differences between both C. 
albicans strains in single colonisation assays were not evident in co-colonisation. The 
differences between the C. glabrata strains were, however, still apparent with highest LDH 
activity occurring for C. glabrata 585626 combined with both C. albicans. In the case of C. 
glabrata 585626 and C. albicans ATCC 90028 co-infection, tissue damage was higher 
than with C. albicans ATCC 90028 alone, despite the initial inoculum of C. albicans ATCC 
90028 being half that used in the single species infection. Based on these findings, it is 
evident that RHVE damage is species and strain dependent with potential synergism 
occurring in mixed species infection.  
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In order to better elucidate pathogenic differences, phospholipase and secreted 
aspartyl proteinase gene expression was measured. A variety of phospholipases (PL), are 
produced by C. albicans and the function of these enzymes includes the metabolism of 
phospholipids in biological membranes. Expression of these enzymes can therefore lead to 
disruption of membrane structure and function [41]. The current study showed that 
expression of PLB and PLD gene families was always detected, with PLD1 expressed at a 
higher level in all single and C. glabrata 585626 co-infections assays, indicating a potential 
role of this factor in RHVE damage. However, these findings contrast with those of Malic et 
al. 2007 [27], where phospholipase gene expression did not correlate with RHOE invasion. 
Assumming that hyphal forms are more adept at epithelium invasion, expression of PLD1 
could be significant in this process as Hube et al., 2001 [42] reported that PLD1 was 
necessary for the yeast-to-hypha transition in Candida albicans.  
The most widely studied extracellular hydrolytic enzymes of C. albicans are SAPs [43–45]. 
This present study revealed that SAP gene expression by C. albicans was strain dependent 
in single and co-infection assays. From qRT-PCR analysis highly invasive C. albicans 
strains, in single infections were consistent producers of SAP4–10. Of note is that Naglik 
et al., 2003 [44] have shown that SAP4–6 are important for yeast-to-hypha transformation. 
It is important to highlight that SAP3 was not expressed by C. albicans 324LA/94, which 
was a ‘high invader’. Korting et al., 2003 [46] determined that the epithelial cell damage 
by C. albicans correlated with expression of SAP3. Based on the results of this current 
study and as indicated by Naglik et al., 2008 [10], it would appear that SAPs do not play a 
significant role in C. albicans invasion and damage of RHVE. 
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Abstract 
Despite Non-Candida albicans Candida species increasingly recognised as new 
pathogenic yeasts, it is generally still the case, that Candida albicans is the most virulent 
species. One of the most important candidal virulence factors is an ability to adhere to 
host surfaces and form biofilms. Candida albicans is responsible for the majority of cases 
of Vaginal Candidosis (VC), an infection which occurs mainly during the luteal phase of the 
menstrual cycle or during the pregnancy, when levels of progesterone are elevated.  
The aim of this study was to determine the influence of progesterone on C. 
albicans virulence, namely biofilm formation and colonisation/invasion of a reconstituted 
human vaginal epithelium (RHVE). Biofilm formation on the RHVE was evaluated by 
enumeration of culturable cells, total mass quantification and scanning electron 
microscopy. The capacity of C. albicans strains to invade and colonise the tissue was 
examined by fluorescence microscopy using species-specific peptide nucleic acid (PNA) 
probe hybridisation, and quantitatively evaluated by RT-PCR Candida quantification 
methodology. Furthermore, gene (BCR1 and HWP1) expression of biofilm and RHVE 
colonising cells was evaluated by quantitative RT-PCR. Results confirmed that progesterone 
reduced the capacity of C. albicans strains to form biofilms and to colonise and invade 
RHVE. Additionally, it was demonstrated that progesterone decreased expression of BCR1 
and HWP1, which are important virulence determinants of C. albicans. In conclusion, it 
was evident that progesterone can have a major influence on C. albicans pathogenicity on 
vaginal epithelial cells and may partly explain susceptibility of women to VC at different 
stages of the menstrual cycle. 
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4.1. Introduction 
Yeast species of the genus Candida are responsible for 70-90% of human fungal 
infections, with Candida albicans accounting for approximately 50% of all yeasts isolated 
from clinical samples [1]. Interestingly, there has been a notable increase in the relative 
proportion of infections caused by non-Candida albicans Candida (NCAC) species [2]. 
However, C. albicans is still regarded to be the most virulent Candida species. Infection 
with C. albicans represents an important public health challenge with high economic and 
medical relevance due to the increased costs of care, time of hospitalisation and high 
levels of morbidity and mortality rates, especially in immunocompromised patients [3].  
Vaginal candidosis (VC) is an opportunistic fungal infection caused by Candida 
species that affects between 29% and 45% of healthy women during their lifetime in 
European countries [4] and approximately 75% of women of gestation age in the United 
States [5,6].  
The pathogenesis of VC involves the initial adherence of the yeast to the vaginal 
mucosa, followed by asymptomatic colonisation, ultimately leading to infection 
(symptomatic vaginitis) [7]. This occurs when the colonisation site of the host becomes 
favourable to the growth of yeast, which is normally restricted to asymptomatic 
colonisation and limited by immunological host responses.  Conditions associated with 
enhanced colonisation include host immunosuppression, diabetes mellitus and pregnancy. 
The use of antibiotics, and oral contraceptives that contain high levels of oestrogen also 
seem to be contributory predisposing factors [5,8]. In the absence of these factors, clinical 
observations show that VC occurs predominantly during the luteal phase of the menstrual 
cycle, when levels of progesterone and oestrogen are elevated. In contrast, pre-menstrual 
girls and post-menopausal women who are not receiving hormone replacement therapy, 
rarely exhibit VC [9]. However, the mechanisms by which these hormones, act in VC are 
not fully known [10,11].  
Amongst the putative virulence factors of Candida are the ability to express 
adhesins to adhere to host tissues and also produce biofilms [12]. Biofilms are microbial 
communities associated with biotic or abiotic solid surfaces. Cells in a biofilm display 
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phenotypes that are distinct from their free-living counterparts, including increased 
resistance to typical antifungal drugs [13,14]. Biofilm formation is, in part, dependent upon 
expression of the C. albicans transcription factor BCR1 (biofilm cell wall regulator) [15]. 
Host cell recognition and colonisation by Candida is also facilitated by adhesins, such as 
Hyphal Wall Protein (HWP) [16], which is expressed by the hyphal form of C. albicans. 
Importantly, the effect of progesterone on expression of these virulence factors is not 
known and could be a contributory influence on Candida biofilm formation and vaginal 
human epithelial colonisation and invasion. 
This current work aimed to investigate the influence of progesterone on C. 
albicans biofilm formation on a reconstituted human vaginal epithelium (RHVE). The 
colonisation/invasion of this tissue by C. albicans was assessed together with the 
expression of BCR1 and HWP1 during C. albicans biofilm development. 
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4.2. Materials and methods 
4.2.1. Organisms and growth conditions 
Two Candida albicans strains were used in this work, which were a reference 
strain C. albicans ATCC 90028 from the American Type Culture Collection (ATCC) and a 
vaginal isolate, namely C. albicans 558234, acquired from the biofilm group of the Centre 
of Biological Engineering, Minho University (Braga, Portugal) and previously isolated from a 
patient of the Hospital of S. Marcos, Braga, Portugal. The identity of the isolates were 
confirmed using CHROMagar®Candida (CHROMagar, France) and by PCR-based 
sequencing using specific primers ITS1 (5´-TCCGTAGGTGAACCTGCGG-3´) and ITS4 (5´-
TCCTCCGCTTATTGATATGC-3´) [17].  
All Candida strains were subcultured on Sabouraud Dextrose Agar (SDA; Merck, 
Germany) at 37ºC for 48 h. An inoculum of each strain, obtained from SDA plates, was 
suspended in 20 ml of Sabouraud dextrose broth (SDB; Merck, Germany) and incubated 
at 37ºC for 18 h under agitation (120 rev/min). Then, the cells were harvested by 
centrifugation at 3000 g for 10 min at 4ºC and washed twice with 15 ml of phosphate 
buffered saline (PBS; pH 7, 0.1 M). Pellets were suspended in RPMI (Sigma, St Louis, 
MO), buffered to pH 4.0 and the cellular density adjusted for each experiment, using a 
Neubauer haemocytometer (Marienfild, Land-Könicshofen, Germany). 
4.2.2. Effect of progesterone on Candida albicans biofilm formation 
In order to study the effect of progesterone on C. albicans biofilm formation, 
progesterone (Sigma Saint Louis, Missouri, USA) was added at the beginning of the biofilm 
formation process. To the wells of 96-well microtiter plates (Orange Scientific, Braine-
l’Alleud, Belgium), 200 µl of Candida suspension containing 1x107 cells/ml with 2 µM of 
progesterone in RPMI (pH 4) was added. The progesterone concentration was selected 
according to the levels present in the plasma of pregnant women in the third trimester 
[18]. The microtiter plates were incubated at 37ºC under agitation (120 rev/min) for 24 h. 
Yeast cultures without progesterone and controls without Candida were also included. After 
incubation, the medium was aspirated and the biofilms washed once with 200 µl of PBS to 
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remove non-adherent cells. All experiments were performed in triplicate and in a minimum 
of three independent assays. 
I- Quantification of cultivable cells from biofilms  
Biofilms were physically removed from the wells using a pipette tip and the 
suspensions were vigorously vortex mixed for 2 min to disaggregate cells. Serial decimal 
dilutions of recovered cells in PBS were plated on SDA and incubated for 24 h at 37ºC. 
The results were presented as total colony forming units (CFUs) per unit area (Log 
CFUs/cm2) [19].  
II- Quantification of biofilms biomass 
Total biofilm biomass was quantified using a crystal violet (CV) staining 
methodology [19]. Biofilms in the microtiter plate wells were fixed with 200 µl of methanol 
for 15 min. The methanol was removed and the microtiter plates allowed to dry at room 
temperature. A 200 µl volume of crystal violet (CV; 1%, v/v) was then added to each well. 
After 5 min, excess CV was removed and the biofilms were gently washed (×2) with water. 
Finally 200 µl of acetic acid (33%, v/v) was added to each well to release and dissolve the 
CV stain. The absorbance of the CV solutions was then measured at 570nm and results 
presented as absorbance per unit area (Abs/cm2). 
III- Characterisation of biofilm structure  
The structure of biofilms and morphology of Candida in the presence and absence 
of progesterone was also characterised by scanning electron microscopy (SEM). 
Preparation of biofilms was as described above, but 24-well microtiter plates (orange 
Scientific, Braine-l´Alleud, Belgium) were used. Developed biofilms were dehydrated with 
increasing concentrations of ethanol (using 70% ethanol for 10 min, 95% ethanol for 10 
min and 100% ethanol for 20 min) and then air dried for 20 min. Samples were kept in a 
desiccator until analysis. Prior to observation, the base of the wells were removed and 
mounted on aluminium stubs, sputter coated with gold and imaged using an S-360 
scanning electron microscope (Leo, Cambridge, USA). 
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4.2.3. Effect of progesterone on Candida albicans colonisation of 
RHVE  
RHVE tissues (SkinEthic Laboratories, Lyon, France) were inoculated for 24 h with 
1 ml of standardised C. albicans suspension (2×106 cells/ml) prepared in maintenance 
medium (SkinEthic Laboratories, Lyon, France) and adjusted to pH 4 in the presence and 
absence of 2 µM of progesterone. Tissues devoid of progesterone or C. albicans were also 
included. To determine the effects of progesterone on the measured parameters, the 
RHVE was also firstly incubated for 12 h with 1 ml (2×106 cells/ml) of each C. albicans 
strain in the absence of progesterone. The tissue was then washed (×1) with 1 ml of PBS 
to remove non-adherent cells and 1 ml of maintenance medium with 2 µM of progesterone 
was added to each tissue. All infected tissues were incubated at 37°C in a 5% CO2 
environment in a saturated humidity for the required time period. After incubation, tissues 
were washed (×2) with 1 ml of PBS to remove non-adherent Candida. Tissues were then 
bisected, with one half being used for fluorescence microscopy and the other for molecular 
studies. 
I- Microscopic observation 
The RHVE half of the tissue for microscopic analysis was fixed in 2% (v/v) formalin 
and stored at 4°C until histological processing. Tissues were then dehydrated, cleared, 
and infiltrated with paraffin wax embedding material. The formalin-fixed paraffin-embedded 
(FFPE) tissues were stored at room temperature. The tissues were cut (5 µm sections) and 
placed on Histobond+ coated microscope slides (Raymond A Lamb, East Sussex, UK), de-
waxed, and processed through xylene, ethanol, and water before peptide nucleic acid 
probe hybridization (PNA FISH). 
PNA FISH was employed on tissue sections using the Light PNA FISHTM kit 
(AdvanDx Inc., Woburn MA, USA). The species-specific PNA probes were used to ascertain 
the extent of invasion and colonisation of the RHVE by C. albicans. The assay was 
performed in accordance with the guidelines of the manufacturer. Tissue sections on 
microscope slides were overlaid with 1 drop of PNA probe. After 90 min of incubation in 
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the dark and in a humidified chamber at 55°C, unbound probe was removed by washing 
the slides using a previously warmed wash solution at 55°C for 30 min. The preparation 
was then mounted with a medium (Vectashield, Vector laboratories, California, USA) 
suitable for fluorescence microscopy, which also contained 4',6-diamidino-2-phenylindole 
(DAPI) for detection of epithelial cell nuclei.  
Tissue sections (5 µm) hybridised with PNA probes were observed by fluorescence 
microscopy, using a BX51 Olympus fluorescence microscope coupled with a DP71 digital 
camera (Olympus Portugal SA, Porto, Portugal). A specific classification scale was used to 
express the level of C. albicans RHVE colonisation. Colonisation categories were as follows: 
extensive (fungal elements totally covered the surface); moderate (fungal elements covered 
a large proportion of surface) and sparse (fungal elements covered only limited areas of 
surface). Similarly, the following categories defined the level of Candida RHVE invasion: 
high (fungal elements totally invaded all RHVE keratinocytes layers); moderate (fungal 
elements moderately invaded the first RHVE top keratinocytes layers) and low (fungal 
elements only formed isolated clusters in the first RHVE keratinocyte layer). 
II- Quantification of Candida cells in RHVE tissue sections 
II.1- DNA extraction 
From the remaining FFPE tissue, four tissue sections of 5 µm were cut and 
placed in sterile 1.5 ml microcentrifuge tubes (Eppendorf AG, Hamburg, Germany). 
Paraffin was removed using 1 ml of xylene and the tubes vigorously vortexed for 10 s. After 
centrifugation (13,000 g for 2 min), the supernatant was discarded and the residual xylene 
removed from the tissue pellet by adding 1 ml of absolute ethanol. After repeat 
centrifugation, the supernatant was carefully removed. The tubes were left open for 10 min 
at room temperature and DNA for PCR analysis was extracted from the tissue pellet using 
a commercial DNA extraction kit (QIAamp® DNA FFPE Tissue, Qiagen). 
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II.2- Quantification of Candida by Real-time PCR 
Candida albicans were quantified using real-time PCR employing a CF X96 Real-
Time PCR System (Bio-Rad, Berkeley, USA). Each reaction mixture consisted of 10 µl of 
working concentration of SsoFast EvaGreen Supermix (Bio-Rad, Berkeley, USA), 0.2 µl of 
each primer (50 µM) designed previously (Forward- 
GAGCGTCGTTTCTCCCTCAAACCGCTGG and Reverse- 
GGTGGACGTTACCGCCGCAAGCAATGTT), and 4 µl of DNA, in a final reaction volume of 20 
µl. Negative controls were performed using a reaction mixture with nuclease free H2O 
(Cleaver Scientific Ltd, UK) substituting for the template DNA. Template DNA for each 
positive control was obtained from FFPE tissues after the step of DNA extraction described 
above. PCR cycling conditions consisted of an initial denaturation step at 98°C for 2 min, 
followed by 40 cycles of denaturation at 98°C for 5 s and primer annealing at 60°C for 5 
s. In each cycle, a dissociation stage of 60°C was run to generate a melting curve for 
confirmation the specificity of the amplification product. Calibration curves (Ct vs. Log 
cells) for each C. albicans strain were constructed using the same PCR protocol as 
described above. For these, serial dilutions of Candida were prepared using an improved 
Neubauer haemocytometer (Marienfild, Land-Könicshofen, Germany) and the DNA for PCR 
analysis extracted from the cell pellet using the DNA extraction kit (QIAamp® DNA FFPE 
Tissue, Qiagen, Crawley, UK) with some modifications. 
4.2.4. Analysis of HWP1 and BCR1 gene expression in C. albicans 
biofilms 
I- Candida RNA extraction 
For gene expression analysis, biofilms were prepared in the presence (2 µM 
progesterone) and absence of progesterone as described above, in both microtiter plates 
and RHVE. In the case of microtiter plate biofilms, the culture medium was removed and 
the wells washed with 1 ml of PBS (pH 7) to remove non-adherent cells. The biofilms were 
then physically removed from wells by scraping with a pipette tip, and resuspended in 1 ml 
of PBS and sonicated (Ultrasonic Processor, Cole-Parmer, Illinois, USA) for 30 s at 30 W to 
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separate the cells from the biofilm matrix. Cells were harvested by centrifugation at 8000 g 
for 5 min at 4ºC and collected in a 1.5 ml microcentrifuge tube (QIAshredder®, Qiagen, 
Crawley, UK).  
For RNA extraction from Candida adhered to tissues, fresh RHVE tissue was 
removed with a scalpel directly from the plastic scaffold and placed in a 1.5 ml 
microcentrifuge tube (QIAshredder®, Qiagen, Crawley, UK). To each microcentrifuge tube 
(QIAshredder®, Qiagen, Crawley, UK) 600 µl of RLT buffer containing 500 µl of glass 
beads (0.5 mm diameter) and 1/100 (v/v) of ß-mercaptoethanol was added. These mixes 
were homogenised twice for 30 s using a Mini-Bead-Beater-8 (Stratech Scientific, Soham, 
UK). After cell disruption, the PureLink® RNA Mini Kit (Invitrogen, Carlsbad, USA) was 
used for total RNA extraction according to the manufacturer’s recommended protocol. To 
remove any DNA contamination, samples were treated with RNase-Free DNase I 
(Invitrogen, Carlsbad, USA). The RNA extraction was performed on three different 
independents assays. 
II- Synthesis of cDNA 
To synthesise complementary DNA (cDNA), the iScript cDNA Synthesis Kit (Bio-
Rad) was used according to the manufacturer’s instructions. For each sample, 0.5 µg of 
the extracted RNA was used for cDNA synthesis. cDNA synthesis was performed firstly at 
70ºC for 5 min and then at 42ºC for 1 h. The reaction was stopped by heating for 5 min at 
95ºC. 
III- Gene selection and primer design for quantitative Real-time PCR 
Primers for the ‘housekeeping´ genes (ACT1_alb), and putative virulence genes 
(HWP1, BCR1) were designed using Primer3 web software (http://fokker.wi.mit.edu). Full-
length gene sequences were obtained from the C. albicans database 
http://www.candidagenome.org [20]. The specificity of each primer was confirmed by 
comparing its respective sequences to the C. albicans database using BLAST [21]. To 
verify the specificity of each primer pair for its corresponding target gene, PCR using the 
various primer pairs was applied to genomic DNA extracted from each of the C. albicans 
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strains. The sequences of the primers developed in the present study are provided in Table 
4.1. 
 
Table 4.1 – Forward (FW) and reverse (RV) primers used for Real-time PCR 
 
 Sequence (5’→ 3’) Orientation Target 
ACT1 gene  
(C. albicans) 
TGCTGAACGTATGCAAAAGG FW 
ACT1_alb 
TGAACAATGGATGGACCAGA RV 
HWP1 Gene 
TCTACTGCTCCAGCCACTGA FW 
HWP1 
CCAGCAGGAATTGTTTCCAT RV 
BCR1 Gene 
CCAGCAGGAATTGTTTCCAT FW 
BCR1 
GGCTGTCCATGTTGTTGTTG RV 
 
IV- Quantitative Real-time PCR (qRT-PCR) 
qRT-PCR (CF X96 Real-Time PCR System; Bio-Rad, Berkeley, USA) was used to 
determine the relative levels of HWP1 and BCR1 mRNA transcripts in the biofilm samples, 
with ACT1 used as a reference housekeeping gene. Each reaction mixture consisted of 10 
µl (working concentration) of SsoFast EvaGreen Supermix (Bio-Rad, Berkeley, USA), 0.2 µl 
of forward and reverse primers (50 µM) (Table 4.1), 5.6 µl of dH2O (Cleaver Scientific Ltd, 
UK), 4 µl of two-fold diluted cDNA samples together with the respective target gene 
primers. Negative controls (dH2O), as well as, non- reverse transcriptase controls (NRT) 
were included in each run. Real-time PCR was performed with an initial denaturation step 
at 98°C for 2 min, followed by 40 cycles of denaturation at 98°C for 5 s, and primer 
annealing at 58°C for 5 s. In each cycle, a dissociation stage at 60°C was run to generate 
a melting curve for verification of amplification product specificity. Control samples were 
included on each plate to ensure that multiple plates could be compared. The Ct value of 
each sample was determined, and the relative gene expression levels calculated using the 
ΔCt method, which was normalised to the housekeeping gene. Each reaction was 
performed in triplicate and mean values of relative expression were determined for each 
gene. 
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4.2.5. Statistical Analysis  
Results were compared using a two-way ANOVA with the Bonferroni test, using 
GraphPad Prism 6 software. All tests were performed with a confidence level of 95%. 
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4.3. Results  
4.3.1. Influence of progesterone on biofilm formation by Candida 
albicans 
Initially, Candida growth curves were determined in RPMI (buffered to pH 4) with 
and without progesterone and no effect was observed in the normal yeast growth (data not 
shown). Then, biofilm formation of two different C. albicans strains, in the presence (2 µM) 
or absence of progesterone, was evaluated using CFU enumeration (Figure 4.1 A) and CV 
staining (Figure 4.1 B).  
 
 
Figure 4.1 – Cell viability [Log (CFU/cm2)] (A) and absorbance values of (B) crystal violet solutions (Abs 
CV/cm2) obtained from 24 h biofilm of C. albicans strains formed in RPMI buffered to pH 4 in absence or 
presence of 2 µM of progesterone. Error bars represent standard deviation. *** Statistical difference obtained 
when compared with absence of 2 µM of progesterone (control) (p<0.001). 
 
It was evident that the presence of progesterone significantly reduced the biofilm 
formation of both strains (Figure 4.1). The number of viable cells [Log (CFUs/cm2)] (Figure 
4.1 A) decreased by approximately 3 Log in case of C. albicans ATCC 90028 (p<0.001) 
and 2 Log in the case of C. albicans 558234 (p<0.001). Similarly, a significant decrease in 
total biomass values (p<0.001) occurred in the presence of progesterone in RPMI medium 
for both Candida strains (Figure 4.1 B).  
SEM analysis was used to examine biofilm structure and to determine possible 
differences concerning Candida morphological characteristics (Figure 4.2). 
A B 
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Figure 4.2 – Scanning electron microscopy of C. albicans 24 h biofilms formed in RPMI in the absence or 
presence of 2 µM of progesterone. Original magnification was ×1000. 
 
Biofilms of C. albicans exhibited different structures and cell morphologies 
depending on culture environment conditions (Figure 4.2). Biofilms formed by both C. 
albicans strains in the absence of progesterone exhibited both yeast and hyphal 
morphology. However, biofilms of C. albicans ATCC 90028 formed a multilayered and 
compact biofilm that covered the entire surface. Biofilms of C. albicans 558234 consisted 
of non-contiguous cell aggregates with less hyphal forms. However, in the presence of 2 
µM of progesterone, biofilms were greatly reduced in cell number and presence of hyphal 
forms. 
Expression of the biofilm cell wall regulator 1 (BCR1) and hyphal wall protein 
(HWP1) genes were determined in an effort to understand the basis behind the observed 
biofilm changes following SEM. Results of these studies are presented in Figure 4.3 and 
expressed as the mean percentage expression, relative to the expression of ACT1 during 
biofilm formation. ACT1 gene expression levels were constant in all assays.  
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Figure 4.3 – Relative BCR1 (A) and HWP1 (B) expression obtained from 24 h biofilms of C. albicans formed 
in RPMI (pH 4), in the presence and absence of 2 µM of progesterone. Error bars represent standard 
deviation. *** Statistical difference obtained when compared with absence of progesterone (p<0.001).
 
The results (Figure 4.3) showed that both BCR1 and HWP1 expression varied in a 
strain dependent manner and with the presence of progesterone. It is important to 
highlight that in the presence of progesterone there was a statistically significant (p<0.001) 
down regulation of genes expression and for both strains.  
4.3.2. Influence of progesterone in RHVE colonisation and invasion by 
Candida albicans 
Candida albicans colonisation and invasion of RHVE was examined after 24 h of 
infection. Progesterone (2 µM) was added at two different time points, at the beginning 
and after 12 h of colonisation (Figure 4.4 and Table 4.2). The addition of progesterone at 
12 h was performed to compare its influence in the development of RHVE infection by C. 
albicans. 
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Figure 4.4 – Candida albicans RHVE infection after 24 h, assessed by fluorescence microscopy and YTL PNA FISHTM. (A) C. albicans ATCC 90028 and (D) C. albicans 558234 
adhered without progesterone, (B) C. albicans ATCC 90028 and (E) C. albicans 558234 adhered for 24 h in the presence of 2 µM of progesterone and (C) C. albicans ATCC 
90028 and (F) C. albicans 558234 with addition of progesterone after 12 h of infection.  
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The results showed that for both strains and in all conditions tested, colonisation 
of the RHVE occurred. However, the degree of colonisation varied with strain and the 
presence of progesterone. Candida albicans 558234 (vaginal isolate) exhibited the highest 
level of colonisation (moderate) in the absence of progesterone (Figure 4.4 D). Under the 
same environmental conditions, C. albicans ATCC 90028 exhibited sparse colonisation 
(Figure 4.4 A). Additionally, both C. albicans strains demonstrated sparse colonisation in 
the presence of progesterone (Figure 4.4 B, E). In general, after 24 h and 12 h exposure 
to progesterone, only a few clusters of C. albicans were detected on the surface of the 
RHVE layers (Figure 4.4 C, F). Furthermore, only C. albicans 558234 appeared able to 
invade the epithelium (Figure 4.4 D, F). 
Real-time PCR was used to quantify the number of infecting C. albicans under the 
different conditions tested (Table 4.2). 
 
Table 4.2 – qRT-PCR quantification of C. albicans infecting the reconstituted human vaginal epithelium for 
24 h in the presence or absence of 2 µM of progesterone 
 
Progesterone 
[2 µM] 
qRT-PCR (Log number of 
cells/ml) 
C. albicans 
ATCC 90028 
C. albicans 
558234 
Control 2.76 ± 0.11 3.56 ± 0.13   
Addition at 0 h 
2.17 ± 0.15 
*** 
2.77 ± 0.21 
*** 
Addition at 12 h 
2.29 ± 0.17 
*** 
2.95 ± 0.13 
*** 
*** statistically different to absence of progesterone (P<0.001). 
 
qRT-PCR showed that both C. albicans strains were present at higher numbers in 
the RHVE sections infected without progesterone (p<0.001), thereby supporting the 
findings of the fluorescence microscopy. There were no discernible differences in terms of 
Candida quantification when progesterone was added at time point 0 or at 12 h.  It was 
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noted that C. albicans 558234 (vaginal strain) was always present in higher numbers than 
C. albicans ATCC 90028.  
HWP1 expression was measured to better understand the effect of progesterone 
on RHVE colonisation and invasion. Figure 4.5 presents the mean n-fold expression levels 
of HWP1 by C. albicans ATCC 90028 and C. albicans 558234 infecting the RHVE. The 
controls represent gene expression in absence of progesterone. 
 
 
Figure 4.5 – Relative expression of the Hyphal Wall Protein 1 (HWP1) gene in the absence or presence 
(added at 0 h, or after 12h) of progesterone during C. albicans colonisation of reconstituted human vaginal 
epithelium. Error bars represent standard deviation. *** Statistical difference obtained compared to the 
absence of progesterone (p<0.001).
 
The results presented in Figure 5, indicate that HWP1 expression was strain 
dependent and was significantly reduced by the presence of progesterone (p<0.001). 
HWP1 expression was dependent on time of contact with progesterone, since after a pre-
period of infection (12 h) without progesterone had higher expression of HWP1 gene 
compared to addition at 0 h. 
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4.4. Discussion 
Vaginal candidosis (VC) is an infection characterised by vaginal inflammation and 
the presence of Candida species. VC is the second most common cause of vaginitis, after 
bacterial vaginosis, and represents approximately one-third of all vaginitis cases [22]. The 
frequency of vaginal colonisation by Candida increases with predisposing risk factors such 
as pregnancy, antibiotic use, immunosuppression, diabetes and HIV infection [6,23]. 
Progesterone is a C-21 steroid hormone involved in the female menstrual cycle, 
pregnancy and embryogenesis. Progesterone levels are relatively low during the pre-
ovulatory phase of the menstrual cycle, rise after ovulation, and are elevated during the 
luteal phase [24]. It has also been shown that Candida has oestrogen and progesterone 
receptors, that when stimulated, increase fungal proliferation [25]. Furthermore, women 
who take oral contraceptive pills (corresponding to constant high levels of progesterone 
and oestrogen) have a higher incidence of VCs [6].  
This current study examined the influence of progesterone on C. albicans virulence 
factors, namely biofilm formation and colonisation/invasion of a reconstituted human 
vaginal epithelium (RHVE). 
Initially, experiments were performed to examine the effect of both oestrogen and 
progesterone on C. albicans biofilm formation. However, preliminary studies with 
oestrogen failed to demonstrate any effects on biofilm formation and therefore the focus 
was directed towards progesterone.  
The effect of progesterone was measured in terms of both number of viable cells 
and total biomass (Figure 4.1) and results were corroborated by SEM (Figure 4.2). 
Oestrogen has previously been shown to be the principle reproductive hormone that 
supports and sustains experimental vaginal C. albicans infection [10]. In contrast, 
progesterone was found to have no demonstrable effect on vaginal infection or on 
associated systemic and/or local immune responsiveness. However, in this present study 
a possible role for progesterone in VC has been highlighted. It is known that one of the 
central regulators of biofilm formation is the factor BCR1 [26–28].  In these current 
studies expression of BCR1 by C. albicans biofilms in the presence of progesterone was 
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significantly reduced (Figure 4.3 A).  Furthermore, SEM (Figure 4.2) revealed a significant 
decrease in hyphal forms of C. albicans, in the presence of the hormone. In efforts to 
explain these findings, expression of hyphal wall protein (HWP1) was also measured and 
again, was found to decrease in the presence of progesterone (Figure 4.3 B). Hwp1 is a 
determinant of C. albicans pathogenicity, and involved in biofilm formation [29,30]. 
Additional studies have shown that reduced HWP1 gene expression results in thin biofilms 
and a significant reduction in hyphal mass [31].  Based on the work of this present study, 
it is possible that progesterone affects C. albicans biofilm structure through modulation of 
the biofilm-associated genes, BCR1 and HWP1. 
In order to investigate the influence of progesterone on C. albicans vaginal pathogenicity, a 
commercially available reconstituted human vaginal epithelium (RHVE, Nice, France) was 
used. It was evident that both tested C. albicans strains could colonise the RHVE (Figure 
4.4 and Table 4.2), with limited clusters of cells present within the upper layers of the 
epithelium and few filamentous forms. However, notably both colonisation and invasion 
substantially decreased in the presence of progesterone, without any apparent alteration of 
the RHVE (Figure 4.4 and Table 4.2). This results are in accordance with those of Špaček 
et al., 2007 [24] who showed that progesterone levels in luteal phase of recurrent VC 
patients (6.40 nmol/L) was lower compared with non-infected controls (34.2nmol/L).  
Down-regulation of HWP1 was evident in the presence of progesterone, as verified 
for biofilms, and was associated with reduced colonisation and invasion. The effect of 
progesterone on HWP1 expression decreased slightly when added after 12 h of the 
infection process. Furthermore, colonisation and invasion of the RHVE by C. albicans 
increased slightly when progesterone was added 12 h post infection compared when 
added at start of RHVE infection. In 1992, Reed [25] had shown that Candida had 
receptors to progesterone and as these were activated, the degree of pathogenicity 
increased. The findings of this present study would appear to contradict the findings of 
Reed (1992) [25], as it would have been expected that a longer exposure to progesterone 
would have led to increased activation of the receptors leading to enhanced pathogenicity, 
this was not the case. Furthermore, C. albicans 558234 expressed higher levels of HWP1 
(Figure 4.5) when progesterone was added 12 h post infection, compared to those 
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infections with progesterone presence for 24 h.  These findings were supported by hyphal 
detection using fluorescence microscopy (Figure 4.4 F).  
In summary, progesterone was able to modulate C. albicans biofilm formation (cell 
viability, total biomass and structure), as well as the colonisation and invasion of RHVE. 
These effects may relate to the down regulation of the biofilm related genes BCR1 and 
HWP1 by progesterone. Additionally, HWP1 gene expression by C. albicans infecting RHVE 
suggests an important role of progesterone in hyphal development. If these effects can be 
extrapolated to the in vivo situation then relative progesterone levels may play important 
roles in the progression of C. albicans vaginal infection. 
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5.1. General conclusions and future work 
Treatment of candidosis is difficult which is partly due to the eukaryotic nature of 
fungal cells limiting the number of antifungals that are without host toxicity. Thus, amongst 
the traditional antifungal agents (azoles, polyenes or echinocandins) there are relatively 
few that are effective for clinical use. Furthermore, due to increased antifungal 
administration, antifungal resistance is becoming increasingly apparent. In order to 
overcome such problems, there is much interest in the potential use of natural extracts 
and compounds as alternative antifungal agents. In this current research, the phenolic 
extracts of Castanae sativa, Filipendula ulmaria, Rosa micrantha and Cistus ladanifer, 
exhibited promising antifungal activity against Candida species, suggesting that these 
compounds could potentially have a role in protection against fungal infections. 
Furthermore, it was demonstrated that these phenolic compounds, and particularly gallic 
acid, affected the growth of different planktonic Candida species. Catechin showed similar 
effect against Candida albicans ATCC 90028 at higher test concentrations. Gallic acid and 
quercetin demonstrated only slight activity against Candida species biofilms. Therefore, it 
should be highlighted that wild plants from the North Eastern of Portugal, and their 
compounds, represent important resources that could be utilised for the treatment of 
Candida that exhibit resistance to the common antifungal agents.  
Future studies should continue to investigate these novel anti-Candida compounds derived 
from North Eastern Portuguese flowers and increase our understanding of their antifungal 
properties. Particular focus should be given to compounds that are effective against 
Candida biofilms, which are particularly problematic in clinical settings. The potential 
cytotoxicity of the most promising compounds should be assessed, in order to facilitate 
use as antifungals in human therapy. 
Infections caused by Candida have increased in recent years, primarily due to the 
increasing number of immunocompromised patients, patients with diabetes mellitus and 
HIV associated diseases. Candida species are the second more common cause, after 
bacteria, of vaginal inflammation. Vaginal candidosis (VC) is an infection of the vaginal 
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mucous membranes caused most frequently by C. albicans. However, it is increasingly 
evident that non-Candida albicans Candida species are emerging as ‘new pathogens’ often 
in association with C. albicans. In this present study, it was confirmed that C. albicans was 
a much more extensive coloniser and invader of a reconstituted human vaginal epithelium 
(RHVE), compared with C. glabrata. However, it is important to highlight that co-infection of 
C. albicans with C. glabrata enhanced colonisation and invasiveness of the latter. To the 
candidate’s knowledge, this represent the first report of HWP1, ALS, EPA, PLB, PLD and 
SAP gene expression in C. albicans and C. glabrata co-infection of vaginal epithelium and 
the results suggested an important role of HWP1, PLD1 and ALS3 in C. albicans and C. 
glabrata pathogenicity.  
Although the present work provided some insights into Candida species vaginal tissue co-
infection and associated virulence, some questions remain. It would be of value to 
investigate the host immune response to C. albicans and C. glabrata single and co-
infection, with inclusion of macrophages or human peripheral blood lymphocytes within 
the model. Furthermore, the assessment of further co-infection models, using for example, 
some important vaginal pathogenic bacteria together with Candida species, would be 
interesting to enhance further the knowledge of the clinical condition, since VCs are often 
polymicrobial.  
Another important factor in Candida pathogenicity is their ability to respond rapidly 
to environmental changes and this flexibility may allow these organisms to take advantage 
of impaired immunity in debilitated patients and facilitate disease. Consequently, the effect 
of an environmental factor (level of hormone) on the infection process was also evaluated. 
It was demonstrated that progesterone reduced C. albicans biofilm formation as measured 
by cell viability, total biomass and structure. Additionally, it was shown that the respective 
biofilm and hyphal related genes, BCR1 and HWP1, were involved in biofilm modulation by 
progesterone. It was further shown that C. albicans was a higher RHVE coloniser in the 
absence of progesterone.  HWP1 gene expression by C. albicans infecting the vaginal 
epithelium would suggest an important role of progesterone in modulating the HWP1 
virulence factor in C. albicans pathogenicity. It would also be of benefit to enhance these 
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investigations using specific deletion mutants to increase the understanding of the role of 
these factors in the control of biofilm formation and adhesion to epithelial cells. Proteomic 
approaches could also be used with the aim to identify which proteins are expressed and 
modulated when local environmental conditions change. 
In addition to the suggestions aforementioned, it is generally known that the use of 
indwelling medical devices is increasing and these are known risk factors in candidosis. 
Consequently further work could also investigate the role of intrauterine devices in 
enhancing Candida colonisation and biofilm formation, to further elucidate our 
understanding of VC.  
In summary, this thesis has revealed the importance of studying natural plant 
extracts and associated individual components as a means to increase the number of 
available antifungal agents for the treatment of candidosis. In addition, inherent differences 
between C. albicans and C. glabrata RHVE pathogenicity were determined and the 
increase of C. glabrata pathogenicity in presence of C. albicans also demonstrated. 
Furthermore, it was also observed that the presence of progesterone decreased the 
capacity of C. albicans to form biofilm and colonise/invade the RHVE. Thus, this in vitro 
work provides potentially valuable information into the pathogenic mechanisms of C. 
albicans and NCAC species. 
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